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SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS: IN SUPPORT OF
TRANSLATIONAL THERAPY

By David Daniel Rushworth, BS

Advisory Professor: Laurence Cooper, M.D., Ph. D.

T cells are blood cells which organize the immune system of the host. These cells are
necessary for the host to respond appropriately to threats from foreign organisms and
cancerous growth. However, in the case of certain infections and cancer, T cells are unable to
respond appropriately to a threat and establish immunity. This leads to disease when the
infection or cancer is not sufficiently eliminated. On the other hand, T cells can lack tolerance
for healthy tissue and perceive healthy tissue as infected. The ensuing over-reactive immune
response also leads to disease. A delicate balance must exist between immunity and tolerance
to prevent these diseases. Small molecules have been developed to ameliorate human
diseases resulting from the failure of T cell immunity or T cell tolerance, but these small
molecules rarely lead to cure. This has driven investigators to develop approaches where T
cells are modified to target disease in order to restore the balance between immunity and
tolerance. The results have been promising and include long-term cure of disease.
Furthermore, genetic modification of T cells has the potential to provide supra-physiological
capacities to T cells, including targeting infection or cancer in ways that T cells could never
achieve naturally within the host. These gene therapy approaches are hindered by technical
challenges such as selecting for genetically-modified T cells and against unwanted T cell
phenotypes. Here we describe novel methods utilizing unique transgenes and small molecules
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aimed at improving the selection of genetically-modified T cells for the treatment of disease in
humans.

ABSTRACT
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Chapter 1: INTRODUCTION
The immunobiology of T cells
Vertebrate animals have evolved a dedicated system capable of removing foreign
organisms from within the animal. This organ is called the immune system. The immune
system is vital to the survival of an animal, and genetic deficiencies within the immune system
typically lead to disease and death at a young age.

The immune system operates in a

characteristic way: Large molecules typically found on bacteria, fungi, or viruses, are
recognized by receptors on innate immune cells in the animal. Innate cells and proteins do not
change over the life of the animal. These innate cells are activated by a foreign threat to
secrete proteins called cytokines and chemokines which mobilize the innate and adaptive
immune system. Adaptive immune cells develop an immune response tailored to remove the
foreign threat. Both adaptive and innate immune cells are typically found circulating in the blood
or resting in immune organs, but when cytokines or chemokines are recognized, these immune
cells travel through the body to the site where the hormones are being secreted.

The early innate immune response involves proteins such as complement and pattern
recognition receptors, as well as immune cells, such as macrophages and neutrophils, which
traffic to these sites.[1] For example, Staphylococcus epidermidus is relatively benign and found
on the skin while Staphylococcus aureus frequently causes infections and disease,[2] but each
activate the innate immune system similarly. One of the first immune cells to arrive in an innate
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immune response is a macrophage. Macrophages engulf foreign organism and cell debris, but
also carry out a crucial role in further activating the immune system.

Macrophages and similar cells called dendritic cells engulf foreign matter associated with
the pathological organism and degrade the foreign matter into smaller components, called
antigens. Macrophages and dendritic cells then present the foreign matter antigens on their
surface bound to a family of proteins known as the major histocompatibility complex or MHC.
The advantage of MHC is that antigens on MHC are recognized by a specialized type of
immune cell known as a T cell. T cells and B cells constitute the portion of the immune system
able to adapt to variations in pathological organisms which the innate immune system cannot.
T cells and B cells therefore constitute the adaptive immune system. Cells like macrophages
and dendritic cells that present this antigen are called antigen presenting cells (APCs).[3]

When T cells recognize antigen: MHC complex on APC, then the T cell become activated
and releases cytokines that activate other immune cells to begin an immune response. The T
cells also begin to replicate and produce more T cells with the same capacity to respond to the
same antigen.[1] Cytotoxic T cell (Tcyt), also known as CD8+ T cells, have the capacity to kill
cells that are expressing target antigen on class I MHC, and this is crucial for the removal of
intracellular pathological organisms such as bacteria and viruses.[4] When B cells are activated
or receive cytokine signal from activated T cells, then B cells begin an immune response
towards antigen present on the surface of foreign organisms. B cells respond to antigens by
generating proteins called antibodies, which bind a specific portion of a given antigen.
Antibodies are an important part of the immune system as they have the capacity to detect
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extracellular and cell surface antigens, and binding of antibodies to foreign matter activate the
innate immune system to bind and destroy foreign organisms.[1, 3]

Antigen response in T cells
The ability of B cells and T cells to bind unique antigens associated with pathogens is
due to a capacity of these cells to reorganize their DNA, an uncommon phenomenon in
animals. The DNA of B cell receptors (BCR) and T cell receptors (TCR) is designed and
systematically reorganized in such a way that the DNA encodes millions of possible BCRs and
TCRs, but after reorganization only one of those possibilities is present in an individual B cell or
T cell. Thus, when a T cell responds to antigen on an APC, the T cell is restricted to that
antigen presented on MHC and will not recognize other antigens or the same antigen when
unbound to MHC. [1]

T cells require the presence of the appropriate antigen presented on MHC to begin
activation, but more signals are needed to fully stimulate the T cell. In fact, if those other
signals are absent, a T cell recognizing antigen on MHC may undergo death or be otherwise
inhibited from normal activation.[3] Cytokines are one of these signals which is important to T
cell survival and activation. Cytokines such as IL-7 and IL-15 help T cells to continue to survive
independent of antigen. However, when T cells recognize antigen, cytokines such as IL-2, IL-4,
IL-12, IL-17, and TGF-β can strongly influence the activation and differentiation of the T cell.[5] T
cell naïve to antigen must receive activation through the TCR as well as costimulatory receptor
activation. The presence of the appropriate costimulatory ligands on the APC is a crucial
component in the activation of T cells.
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Figure 1 Factors influencing T cell activation and propagation

A) The proteins on T cells involved in transducing external signal into internal signals are
shown. Antigen on MHC of APC stimulates TCR, costimulatory receptor detects costimulatory
ligand on APC, and cytokine receptors detect cytokines. B) The strength of stimulation of TCR
alone is insufficient to activate and propagate T cells. Consequently, costimulatory receptors
and cytokines strongly influence the capacity of a T cell to propagate in response to antigen.
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A costimulatory molecule like CD28 has the capacity to fully activate a T cell and initiate an
immune response when CD86 is present on the APC or inhibit the T cell from responding when
CTLA-4 prevents binding of CD28 to CD86.[6] A strong activation signal has the potential to
promote activation, proliferation, and survival. T cells survival after infection can last many
years and prepare the animal to respond more rapidly to a future infection of the same
pathogen. This phenomenon of T cell survival and enhanced response is called T cell memory.
T cell memory is clearly advantageous as many pathogens are ever-present in the environment
of an animal, and survival depends on the ability to deter an initial infection and prevent
repeated infections.[7]

Natural suppression mechanisms of T cells
T cells are quite powerful effectors of the immune system, but T cell activity can be
deleterious if inflammation persists too long or in the absence of an actual pathogen. It is
hypothesized that one of the evolutionary reasons for using multiple signals to fully activate T
cells is that an inappropriately activated T cell could recognize antigens that naturally occur in
the body of an animal. Typically T cells develop in such a way that many of these self-reactive
T cells (T cells responding to self as though it were a foreign pathogen, also called autoreactive) are deleted in the thymus before the auto-reactive T cell is capable of leaving the
thymus to target self-antigen on healthy tissues. However, some auto-reactive T cells continue
to persist within the body usually in a state of suppressed activity.[8] While multiple mechanisms
of immune system suppression exist, suppression mediated by a subset of T cells called
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regulatory T cells – Treg - is considered one of the most effective means of T cell suppression
within the body. [9]

Tregs responds to antigen via TCR like other effector T cells (Teff) and Tcyt, but, unlike
other T cells, the TCR of Treg is reactive towards self and induces suppression of inflammation
when activated. While Treg previously were considered a controversial topic in immunology,
these cells have come to be understood as critical for the maintenance of immune homeostasis
in the body. As an understanding of Tregs developed it was found that loss of a specific
transcription factor, FoxP3, leads to the absence of Treg and, subsequently, severe
autoimmunity in mice and humans from an early age. Treg suppress immune responses through
a variety of mechanisms listed in Table 1. These suppressive mechanisms each inhibit Teff and
Tcyt function to prevent autoimmunity.[10]
Teff, commonly called CD4+ T cells in the literature, often coordinate initiation of an
immune response including innate immune cells and B cells, in order to remove pathogen.[3, 5]
Teff and Treg are both CD4+ and differ from Tcyt by responding to antigen presented on class II
MHC rather than class I MHC. Treg inhibit the inflammatory state from persisting to the point
where it becomes deleterious. Equally, Treg inhibit Teff from initiating and propagating an
immune response towards self-antigen which would be deleterious under healthy conditions.
However, an immune response towards self is at times warranted in the case of somatic
mutations that initiate and propagate cancer. In the case of cancer, Treg suppression of
autoimmunity is deleterious as it prevents a cancer-specific immune response.[11] Clearly, the
ratio of Teff to Treg can be crucial to the prevention of pathology. As such, many clinicians and
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Table 1 Suppressive mechanisms of Treg

Mediator

Abbreviation

Adenosine

Mechanism
Signaling via the A2a receptor to generate cAMP

3`-5` Cyclic adenosine

cAMP

Inhibitory secondary signal to effector lymphocytes during
[14]

monophosphate
Transforming

[12, 13]

intercellular contact.
growth

TGF - β

Inhibitory signaling to multiple cell types

CTLA – 4

Inhibitory costimulation to T cells.

[15]

factor - β
Cytotoxic T Lymphocyte

[16]

Antigen -4
CD25

This portion of the IL-2 receptor is overexpressed and acts as
[17]

a sink for the T cell activator IL-2
Interleukin-10
Indoleamine
deoxygenase

–

2,3

-

[17]

IL-10

Suppressive cytokine

IDO

Depletion of Tryptophan and arylhydrocarbon receptor
[18]

activation
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researchers have begun to use T cell therapies to treat diseases of inflammation or immune
suppression.

Application of T cells in the treatment of disease
The clearance of infections in humans requires functional adaptive immunity. Vaccines
co-opt functional T cells and B cells to develop immunologic memory towards dangerous
pathogens. The memory established by vaccines leads to an immune response during early
signs of infection from a pathogen. This use of T cells and B cells has prevented an untold
amount of morbidity and mortality related to overwhelming pathogenic infections, by early
suppression of infection or disease pathology. The success of vaccines has motivated
researchers to develop therapeutics for patients with dysfunctional immune responses.
Researchers have successfully targeted immune suppression in cancer or chronic infections
with cytokines and antibodies. This has proven quite effective in reducing the burden of many
forms of chronic disease due to a weak immune response. In the case of an excessive immune
response, such as autoimmunity, clinicians have also utilized cytokines and antibodies to inhibit
the abnormal immune response.[19] With much development in the way of immunologic
modulation, adoptive transfer of T cells remains elusive in the treatment of disease beyond a
small number of Phase I and II clinical trials. Although these cells are crucial for mounting,
maintaining, and suppressing an immune response, no adoptive T cell therapy has been
formally approved for use in the United States.[20]
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T cells to treat cancer
Targeting T cells to human disease has been in progress for more than 25 years.[21] The
initial aim of clinical trials was to direct T cells to target and kill diffuse cancers such as
metastatic melanoma and leukemia.[21,

22]

With the objective of targeting unusual antigens

present only on the cancer. Antigens on cancers are often times overexpressed or mutated
versions of proteins found on normal cells. Although cancer antigens ideally demarcate only the
cancer, this is rarely the case and the risk of off-tumor toxicities can occur and cause serious
complications that many times have led to morbidity and death. The powerful nature of T cell
therapies is one of the reasons that T cells continue to be sought as a therapeutic, but have not
yet reached FDA approval in the United States for any form of disease.

T cell therapies are consistently improving and begun to incorporate more complex
ideas such as transgenic modifications that perform supraphysiological actions. An early idea
of combining the activating domain of a TCR with the antigen specificity of an antibody (Figure
2) developed a protein called a chimeric antigen receptor (CAR) which activates a T cell
expressing CAR when antigen is recognized on the surface of a cell.[23] This approach is
advantageous as it extends the capacity of T cells to detect antigens not present within MHC.
However, the risk of off-tumor toxicity continues for the same reason. CAR expression on T cell
is a technological challenge that has improved with advances in gene therapy. Now, technical
aspects of T cell culturing techniques and gene therapy are at a point where multiple clinical
trials generate tumor-specific T cells or genetically-modified CAR+ T cells to target cancers.[24-26]
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Figure 2 Comparison of chimeric antigen receptor (CAR) to TCR.

A) The structural differences between a second-generation CAR and endogenous TCR are
displayed with identification for each domain. B) Selective targeting of CAR to surface antigens
independent of MHC is represented. CAR activates T cells to kill cells containing the target
antigen, without killing cells that do not express antigen.
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While many of the T cell clinical trials are showing strong benefit over standard of care,
the cost of producing a T cell therapy and risk to the patient continues to hamper development
of these technologies beyond a few specialized centers. Further limitations exist due to the
complex immunosuppressive environment of the tumor, and difficulty of identifying appropriate
tumor antigens.[25] It should be noted that T cell therapeutics in cancer were initially developed
for the treatment of melanoma and leukemia, and in the intervening quarter century have not
significantly deviated from those cancer targets. Further improvements in the technical aspects
of T cell therapy as well as continuing research and development of immune-modulatory drugs
will continue to promote T cell cancer therapies for cancer and potentially broaden the
applicability of these therapeutics.

T cells to treat infection
A competent immune system can often develop an appropriate immune response to
bacterial and viral antigens leading to initial clearance of the pathogen and long term immunity.
However, not every patient has a competent immune system. In fact, patients who receive a
transplanted organ are chronically immunosuppressed. Patients on immune-suppressive
regimens are at risk for infection from organisms not typically pathogenic in the normal
population. Also, viral infections, which previously led to mild and moderate illness, can be lifethreatening. This risk is most severe in the hematopoietic stem cell transplant (HSCT) setting
where depletion of innate immune cells combines with immune-suppression to prevent MHC
mismatching between bone marrow graft and the body of the host. High doses of
immunosuppressive drugs put the patient at risk for viral, bacterial, and fungal infections, but
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are necessary to prevent deadly graft versus host disease (GvHD). In this case, the appropriate
memory T cells may not exist in sufficient quantities to fight off infection following the high dose
chemotherapy and immunosuppression used to condition the patient for HSCT. This clinical
need was addressed with T cell therapy, and T cells specific to viral infections began
development more than 20 years ago. While this approach of T cell therapy has faced technical
challenges, the risk of off-target toxicity and decreased efficacy are not as great as targeting
cancer. T cells targeting common viral infections such as CMV, EBV, or adenovirus are up to
Phase III clinical development at multiple institutions in the United States and at a similar stage
in Europe.[27]

T cells to treat inflammation
Diseases of excessive inflammation are currently targeted by immune-modulatory or
immune-suppressive medications. These therapies are often effective, but have untoward side
effects as discussed in the above section. Better targeted immunosuppression may be possible
using Tregs. As Tregs are better understood and culturing techniques become more advanced,
cell therapies based on reconstituting Tregs will likely move toward clinical trials more rapidly.
The use of Tregs in clinical trials has been limited to preventing GvHD following HSCT for the
most part. It is likely that the number of uses for Treg will expand as many other forms of
inflammation have been targeted in preclinical models. Technical challenges related to the
isolation and propagation of Treg is currently limiting the advance of this T cell therapy.[10]
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Selection for T cells in the treatment of disease
A common theme in section 1.2 was the technical limitations of T cell therapies. While
development of more effective and safer T cell therapies at times awaits an improved
understanding of immunobiology, there is still a great deal of improvements to be made in the
technical knowledge of T cell isolation, propagation, and re-infusion. Technical knowledge and
expertise continues to advance the field. It often permits biological studies that advance
knowledge as well as new and improved applications for T cell therapies. Here we consider in
further detail methods for the isolation and propagation of T cells.

Antigen-specificity dependent selection (ASDS)
The isolation of T cells based on antigen specificity can be considered an advantage of
working with T cells. A T cell that recognizes an antigen of interest can activate and propagate
itself to larger numbers. However, the MHC restriction of T cell antigens often limits the
feasibility of this approach. Thus, APC must be derived from the patient, or MHC matched
donor, to stimulate their T cells, which was the original ASDS method.[28] Methods using APC
involves isolation and infection of donor APC with virus or activation and pulsing of antigenic
peptide on derived APC. The infected or activated APC then presents antigen to T cells which
activates and propagates antigen specific cells.[28] Alternatively, if the patient has a common
MHC then other approaches are available. Artificial APCs (aAPC) made by geneticallymodifying tumor cells to express specific MHC and peptides can be used to propagate T cells
targeting the MHC - peptide combination.[29, 30] Similarly, synthetic multimer proteins containing
a specific MHC – peptide combination can be used to isolate T cells specific to that MHC
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Figure 3 Common ASDS techniques for T cell selection.

The selection of T cells using ASDS techniques occurs through three common practices.
Shown on the left is ASDS of T cells using donor derived APC. These APCs present antigen on
every MHC the donor expresses – hence there are 12 MHC on the donor-derived APC. In the
center, is an artificial APC (aAPC) expressing one MHC, as aAPC are typically manufactured
expressing one MHC. The same selective propagation of T cells is achieved by only one MHC
peptide complex, which decreases the variety of antigen-specific T cells that are propagated.
Similar to aAPC, on right, T cells can be selected with a multimer (seen as a tetramer), that can
bind T cells specific to a certain MHC-peptide combination and then be purified via this method.
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peptide combination.[31] ASDS methods are quite effective, but are limited by the specificity of
the TCR. Selection of T cells using APC from the same donor propagate T cells specific to
multiple antigens of the peptide presented on multiple MHC (There are up to 12 different MHCs
expressed by the same individual), but extracting and modifying host APC adds technical
challenges to T cell therapy production. Artificial APC selection does not require APC
modification for each donor, but generation of aAPC is a costly task, which results in a
restricted array of MHC choices for presenting antigen to T cells. The use of multimer MHC
technology does not require artificial or donor APC, but producing a multimer is a costly task
and multimer MHC peptide complexes are typically limited to common MHC presenting a
common peptide. Consequently, the T cells generated using aAPC and multimer MHC
techniques target T cells to antigen within a limited population of donors and with a limited
number of antigen targets. This restricted antigen specificity of aAPC and multimers increases
the risk that the T cell response will be insufficient to eradicate disease. Subsequently, MHC
restriction of T cells has become a limitation in generating T cell therapies, and many groups
have focused on propagating cells by antigen-specificity independent selection.

Antigen-specificity independent selection (ASIS)
The development of MHC independent T cell propagation methods has been a great
technical advance for T cell therapies. Growing T cells by ASIS generates large numbers of T
cells for reinfusion to a patient. While it might seem counterintuitive to grow T cells without
direct selection for specificity, the large number of T cells typically includes an activated and
propagated subset of T cells that are specific to the antigen targeted. A possible advantage
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over ASDS is that T cells grown by ASIS may have many different types of T cells specific to
the same disease. In the case of T cells derived from tumor, also known as tumor infiltrating
lymphocytes (TIL), the in vivo development of multiple tumor-specific T cells led to better
suppression of disease than a single tumor specific T cell.[32] Also, the use of ASIS permits T
cells to be genetically modified and propagated without selection. This is commonly used in TIL
and CAR therapies where the specificity of the T cell is not selected in vitro but once infused
leads to ASDS within the patient.[33] The use of ex vivo expansion via ASIS and in vivo
expansion by ASDS could be considered the current standard in T cell therapies.

Generating T cells by ASIS requires stimulators of T cell activation and propagation
such as stimulation, costimulation, and / or cytokine signals.[26] The propagation of T cells
independent of MHC increases the risk for expanding deleterious T cells that might cause
toxicity.[22] In the case of cancer, ASIS techniques propagate Treg along with Tcyt. Consequently,
a T cell therapeutic that is developed to target and destroy tumor may propagate cells that
prevent T cell activity at the site of tumor.[34] On the opposite spectrum of Tcyt activity, Tcyt may
begin to recognize antigen on healthy tissue and target vital organs for destruction.[8] These are
just a few of the examples of poorly modulated T cell activity. The issues of poor efficacy and
off-target toxicity are critical considerations for the field of T cell therapeutics to move forward.
Some of the issues have biological solutions, such as the use of IL-7 or IL-15 rather than IL-2
to decrease Treg ASIS.[26] However, other issues require a more complex approach.

Adoptively transferred host-reactive T cells can become life-threatening when T cells
begin to react to host antigens on vital organs. Therefore, selective depletion of adoptively
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transferred host-reactive T cells is needed in arguably any ASIS propagated T cell therapy.[25]
The field has found no unanimous solution to selectively deplete host-reactive T cells. Most
groups seriously addressing this issue have determined genetic modification of T cells to be the
most effective means to selectively deplete these cells.[35, 36] As host-reactive T cells have the
same potential as tumor-reactive T cells to undergo ASDS in the host, an ex vivo selection
method is needed before adoptive transfer of T cells. Transgenic CAR or TCR did not require in
vitro selection by ASIS, as these approaches develop in vivo ASDS. However, transgenes not
involved in direct targeting of pathology do require in vitro selection by an ASIS method. Thus,
groups have genetically modified T cells for selective depletion in the case of host-reactivity
using in vitro ASIS. Currently, few transgenic ASIS methods have been described to uniformly
select a transgene. Sorting for the desired transgene co-expressed with a surface marker is the
typical methodology with the surface marker selected using magnetic beads.[37-39]

While magnetic bead based sorting has shown efficacy, it is time consuming and costly
as the number of antigens to be sorted increases. Fluorescence based flow sorting techniques
could avoid some of the technical pitfalls of magnetic sorting, but this approach is even more
costly and time consuming.[40] Sorting cell products through large machines, possibly several
times, increases the risk of contamination, which is a serious concern in immune-compromised
patients receiving these therapies. It is apparent that another form of in vitro ASIS for transgene
expression is needed. Hence, we have determined that there are technical limitations in
transgenic selection methods, which are preventing T cell therapeutics from advancing to a
more consistent and safe form of treatment. We have found potential methods that could be
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modified to develop safe, non-immunogenic [41] in vitro ASIS selection for genetically modified T
cells. Our objective is to develop in vitro ASIS methods to select for the expression of
transgene in T cells. The long-term goal is to disseminate these approaches in order for the
field to develop better transgenic methods to control activation, propagation, and depletion of
genetically modified T cells in vivo. We have developed the following hypothesis for this
purpose:

Hypothesis

We find the lack of in vitro ASIS methods for T cell therapeutics to be a major limitation
in the development of higher quality and more complex disease modifying T cell therapies.
Novel ASIS methods are sought to enhance the selection of transgenic T cells and desirable T
cell phenotypes. While in vitro ASIS using chimeric cytokine receptors

[42]

is a recently reported

method of non-immunogenic selection, it only utilizes the third signal in T cell activation –
cytokine signaling. We hypothesized that aAPC can complete this in vitro ASIS methodology by
utilizing the first and second signals of T cell activation (CD3 and costimulatory signaling) of
human genes to activate and propagate T cells independent of antigen specificity.

Following our above argument, a single selection method (i.e. surface-expressed
marker) is limiting the development of more advanced T cell therapeutics. Hence, we sought
another in vitro ASIS method independent of surface-expression. The original in vitro ASIS
techniques, selection with toxic drug by expressing a drug resistance transgene,[43, 44] suffered
from the immunogenicity of the transgene origin – bacteria.[45] Here we hypothesize that the
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lower immunogenicity of mutated human transgenes will establish resistance to antithymidylate drugs as a new in vitro ASIS method. This method will have the advantage of
potentially allowing for in vivo ASIS to a whole class of FDA approved drugs.[46] It is our overall
hypothesis that these non-immunogenic in vitro ASIS techniques will guide development of
better in vitro and in vivo ASIS of T cell phenotypes such as Treg, Teff, or Tcyt and the capacity to
better control the activity of the T cell.

Specific Aims

Specific Aims 1

We sought an AaPC that could select for and propagate T cells independent of antigen
specificity by targeting a conserved exo-domain of CAR+ T cells. This AaPC would ligate and
propagate T cells through CAR independent of antigen specificity.

Specific Aims 2

We determined that transgenic selection with toxic drug would best be achieved with
non-genotoxic drugs. The thymidine synthesis pathway was targeted as it is well described,
non-genotoxic, and often used clinically to suppress T cell proliferation and cancers. Two
enzymes in the thymidine synthesis pathway, dihydrofolate reductase (DHFR) and thymidylate
synthase (TYMS) have an entire class of drugs designed to target these enzymes. We
developed anti-thymidylate resistant mutants of DHFR and TYMS to achieve in vitro ASIS of
transgenic T cells.

Specific Aims 3
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Utilizing the transgenic in vitro ASIS techniques above, we sought a novel ASIS method
to select for or against Tregs. We dissected the T cell suppressive effects of the anti-thymidylate
methotrexate (MTX) to develop a drug-based method for selecting Treg. This improved
understanding of Treg physiology led to the finding that a common antibiotic drug class aminoglycosides - depletes Treg. Hence, transgenic in vitro ASIS techniques advanced the
understanding of selection for T cell phenotypes
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CHAPTER 2: In vitro ASIS of CAR+ T cell for testing and clinical
expansion using aAPC
This chapter is presented without substantial modification from the following publication:

Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee D, Cooper LJ:
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric
antigen receptor independent of specificity. Journal of immunotherapy 2014, 37(4):204-213.

The Journal of Immunotherapy has given permission to republish this work here

Introduction:
The adoptive transfer of antigen-specific T cells is a rapidly developing field of cancer
immunotherapy with innovative approaches to their manufacture being tested and new
antigens being targeted. T cells can be genetically-modified for immunotherapy to express
chimeric antigen receptors (CARs) that recognize tumor-associated antigens (TAAs)
independent of HLA (editorial note: HLA is the human version of MHC) expression. Recent
results from early-phase clinical trials demonstrate that CAR+ T-cell (CART) therapies can lead
to partial and complete remissions of malignant diseases, including in some recipients with
advanced/relapsed B-cell tumors.[47, 48]

Currently, many CART therapies are based upon ex vivo propagation from the donated
T cells obtained from steady-state apheresis or venipuncture.[49-54] Approaches for numeric
expansion typically use either CAR-independent T-cell proliferation based upon cross-linking
CD3 and CD28 with antibodies[50-52, 55] or CAR-dependent propagation using TAA expressed on
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artificial antigen presenting cells (aAPC).[56-59] Other methods to selectively propagate T cells to
constitutively express CAR include co-expression with transgenes for selection under cytocidal
concentrations of drug and/or sorting, such as using magnetic beads that recognize introduced
proteins co-expressed with CAR.[56],[37] After electro-transfer of DNA plasmids derived from
Sleeping Beauty (SB) system, we employ CAR-mediated expansion to selectively propagate T
cells that stably express the introduced single-chain immunoreceptor by repeated additions of
γ-irradiated K562 cells genetically modified to co-express costimulatory molecules and the TAA
targeted by the introduced CAR.[49,

57, 60]

However, this necessitates that each aAPC design

must be manufactured to express the TAA targeted by a given CAR. Furthermore, some TAA
that are biochemically or structurally complex, such as glycosphingolipids, are difficult to
recapitulate on the surface of aAPC.[61]

Here, we describe an approach to achieve CAR-mediated expansion that avoids the
requirement for cytotoxic drugs, magnetic selection, or TAA-specific proliferation. A monoclonal
antibody (mAb, clone 2D3), previously reported by our laboratory,

[57]

was shown to bind to the

conserved exodomain (derived from modified human hinge and Fc region of IgG4)

[62]

of a

CAR. The antigen-specificity of this mAb was constructed as a single-chain variable fragment
(scFv) and expressed on K562 cells to serve as an aAPC.[49, 63] This scFv on the cell surface of
aAPC is able to ligate a panel of CARs with diverse specificities that contain the IgG4
extracellular scaffold, leading to selective expansion of genetically modified T cells that have
redirected specificity for multiple TAAs. This scFv serves as a ligand for CAR (designated
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CARL) that can substitute for TAA and thus provides investigators with one source of aAPC
that may be used to generate populations of CAR+ T cells with any specificity.

Materials and Methods:
Cells and culture conditions

K562 cells (European Collection of Cell Cultures through Sigma-Aldrich, St. Louis, MO;
Cat. No. 89121407), noted for expression of desired endogenous adhesion molecules and the
absence of most HLA class I and all class II molecules,

[63]

were used to derive CD19+ and

CARL+ K562 that served as aAPC. Immortalized tumor targets CD19neg, GD2+ EL-4 murine
thymoma (Cat. No. TIB-40) and CD19+, GD2neg NALM-6 (pre-B cell leukemia, Cat. No. CRL1567) were purchased from American Type Culture Collection (ATCC, Manassas, VA). Identity
of cell lines was validated by the MDACC Cancer Center Support Grant Characterized Cell
Line Core using short tandem repeat DNA fingerprinting. Peripheral blood was donated by
consenting healthy volunteer adults at Gulf Coast Regional Blood Center (Houston, TX).
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Paque Plus density
centrifugation (GE Healthcare Biosciences, Piscataway Township, NJ; Cat. No. 17-1440-02)
before freezing in a mixture of 10% DMSO (Sigma, Allentown, PA; Cat. No. D2650), 50% heatinactivated fetal bovine serum (FBS-Thermo Scientific Hyclone, Bridgewater, NJ, Cat. No.
SH30070.03), and 40% RPMI 1640 (Thermo Scientific Hyclone; Cat. No. SH30096.01). All
cells were cultured in a 37º C humidified incubator with complete media (CM) prepared from
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RPMI 1640, 10% heat-inactivated FBS, and 2 mM GlutaMAX supplement (Life Technologies,
Grand Island, NY; Cat. No. 35050061).

DNA expression plasmids

Codon-optimized CD19RCD28mZ (CoOp)/pSBSO,
transposition sites mediated by SB transposase,

[64]

[57]

which codes for CAR between

was used as the vector backbone for

cloning of the following transgenes. The DNA plasmid 19G4CAR (also designated
CD19RCD28,

[65]

Figure 4A) codes for a 2nd generation CD19-specific CAR containing a

modified IgG4 exodomain, CD28 transmembrane, and CD28/CD3ζ endodomain. The synthesis
of DNA plasmid GD2G4CAR (Figure 4B), specific to sphingolipid GD2, utilized the same
19G4CAR backbone. The GD2-specific scFv derived from murine mAb (clone 14G2a)

[66]

was

commercially synthesized (Geneart, Life Technologies) as codon-optimized cDNA with NheI
and XmnI restriction enzyme (RE) sites flanking the scFv. The 19G4CAR plasmid backbone
and GD2-specific scFv cDNA were excised using these REs and ligated to replace CD19specific scFv with GD2-specific scFv. A DNA plasmid (Figure 4C) coding for a control CAR that
contains no scFv region, designated G4CAR, but does contain an Igκ-FLAG peptide sequence
(METDTLLLWVLLLWVPGSTGDYKDEGTS), was derived from 19G4CAR using primerdirected PCR amplification from the beginning of the IgG4 domain hinge (primer
5’GGTACCTCTGGGGGGCAGGGCCTGCATG3’) to the terminus of the CD3 domain (primer
5’GGGCCCAGCGCTGAGAGCAAGTACGGCCCTCCC3’) and sequence verified. The G4CAR
was ligated into the 19G4CAR backbone ApaI and KpnI RE sites. DNA plasmid coding for a
CD19-specific CAR with no IgG4 (Figure 4D), designated 19CAR, encodes from amino to
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carboxyl termini a GM-CSF (amino acid 1-22; NP_758452.1), CD19-specific scFv (245 amino
acids), CD8α extracellular domain and hinge (amino acids 136-203; NP_001759) followed by
the same CD28 transmembrane and CD28 and CD3ζ domains as other CARs.[65] The full
length of this transgene was synthesized by GeneArt, cut with ClaI and SpeI REs, and ligated
into the 19G4CAR backbone replacing the 19G4CAR codon, which had been excised using
EcoRV and SpeI. The scFv sequence of CARL was derived from the cDNA library of the 2D3
hybridoma.[57] This was achieved by extracting RNA from 5x106 cells using the RNeasy Mini Kit
(Qiagen, Gaithersburg, MD; Cat No. 74104) according to manufacturer’s protocol. A cDNA
library was generated by reverse transcription using oligo-dT primers per the protocol provided
in the Superscript III First Strand kit (Invitrogen; Cat No. 18080-051). PCR (using Amplitaq
Gold) was performed on the cDNA using the degenerate primers for the FR1 region

[67]

to

amplify the mouse VH and VL regions. The VH and VL amplified products were ligated into the
TOPO TA vector and sequenced. The CARL construct for surface expression on aAPC was
composed of GM-CSF leader peptide (amino acid 1-22; NP_758452.1) fused to the 2D3derived scFv, and tethered by CD8α (amino acid 136-182; NP_001759.3) to the
transmembrane and intracellular portions of CD28 (amino acid 56-123; NP_001230006.1)
followed by CD3ζ (amino acid. 48-163; NP_ 000725.1) intracellular domain. Design of all
transgenes utilized Vector NTI Advance™ 11 software (Invitrogen). All transgenes were human
codon optimized before synthesis at GeneArt. The CARL construct was excised and ligated
into a SB expression plasmid, designated Zeo-2A-CARL (Figure 4E), to co-express a zeocin
resistance gene linked via a modified T2A peptide sequence- (amino acids
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Figure 4
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Figure 4 Vector maps for expression of transgenes. Each DNA plasmid expresses a transgene
of interest under promoter human Elongation Factor 1 alpha (phEF-1α), using the beta
hemoglobin poly-adenylation signal (BGH) to terminate transcription. The indirect repeats /
direct repeats (IR/DR) allow for transgene transposition into the genome using SB11. All
plasmids were propagated in bacteria using the origin of replication ColE1 and Kanamycin
resistance (KanR) under the promoter pKan. A) 19G4CAR demonstrates the original plasmid
design used in these studies and shows NheI and XmnI restriction enzyme (RE) sites used to
generate B) GD2G4CAR from PCR-directed truncation of CD19-specific scFv on 19G4CAR
which led to the generation of C) G4CAR and final ligation using ApaI and KpnI REs. D) 19CAR
was designed without an IgG4 exodomain, instead expressing the CD8α hinge and exodomain.
E) Zeo-2A-CARL, expressing CARL, and F) CD19-2A-Neo, expressing truncated human CD19
(tCD19), were designed to express CARL or CD19 on aAPC under drug selection conditions.
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ATGEGRGSLLTCGDVEEPGP). Truncated human CD19 was synthesized by GeneArt
containing the extracellular and transmembrane portions of human CD19 (amino acid 1-313;
NP_001171569.1). This gene was excised and ligated into SB DNA plasmid, designated CD192A-Neo (Figure 4F), to co-express with neomycin phosphotransferase linked via a modified
F2A peptide sequence (amino acids (G)4S(G)4SVKQTLNFDLLKLAGDVESNPGP).

Artificial antigen presenting cells (aAPC)
CARL+ and CD19+ aAPC were derived by the independent electroporation of parental
K562 cells with Zeo-2A-CARL or CD19-2A-Neo and SB11 transposase DNA plasmids using
the Amaxa 2D nucleofector under program T-16 with Kit V (Lonza, Allendale, NJ; Cat No. VCA1003). After 3 days incubation, each transfection was placed under drug selection in a 6-well
plate using either 0.5 mg/mL Zeocin or 1 mg/mL G418 for Zeocin resistance or Neomycin
resistance, respectively (Invivogen, San Diego, CA; Cat. No. ant-zn-1 and ant-gn-1). This was
achieved by dispersing 10,000 cells with drug in 3 mL semi-solid Methocult H4230 media
(StemCell Technologies, Vancouver, BC, Canada; Cat No. 04230). After 10 days visuallyperceptible individual (clonal) colonies were transferred to individual flasks and grown in CM.
Each clone was tested for uniform expression of CARL or CD19 using flow cytometry. Clones
of CARL+ (designated Zeo-2A-CARL MC5) and CD19+ (designated CD19-2A-Neo MC2) aAPC
were grown to large numbers, γ-irradiated at 100 cGy, and cryopreserved. Before freezing, the
aAPC were routinely tested for the presence of transgenes, absence of mycoplasma, and
absence of endotoxin.
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Propagation of CAR+ T cells (CART)

The designs of each CAR and antigen (CARL and CD19) as expressed on the
respective T cell or aAPC are shown in Figure 5A. The propagation of CART is depicted in
Figure 5B. Each CAR from Figure 5A.II was co-cultured with aAPC from Figure 5A.I. At the
initiation of the experiment (defined as Day 0), thawed PBMC were washed twice, and
maintained in CM for 3 to 4 hours before electroporation using the Amaxa 2D Nucleofector
under program U-14 with human T cell Nucleofector kit (Lonza Biosciences; Cat No. VPA1002). After resting overnight in CM, viable PBMC (counted by exclusion of 0.1% Trypan Blue)
were resuspended in CM and mixed at a 1:2 ratio (mononuclear cell to γ-irradiated aAPC) using
thawed aAPC that were washed twice and counted. The co-culture contained 106 total cells/
mL in CM and 50 IU/mL recombinant human IL-2 (Proleukin, Prometheus Labs, San Diego,
CA). The live-cell counts were determined by Trypan Blue exclusion on Days 1, 7, 14, and 21
of co-culture. Flow cytometry for CD3, CD4, CD8, and human IgG (to assess CAR expression)
occurred on Days 1, 7, 14, and 21, and for CD45RO, CD62L, and CD28 occurred on Days 14
and 21. Irradiated aAPC were re-added to co-cultures on Days 7 and 14 by re-stimulating
mononuclear cells with γ-irradiated aAPC at 1:2 ratio. On Day 21 products of propagation were
assessed for specific killing, and DNA and RNA were extracted. Each experiment was repeated
at least 4 times using 5 donors.

Flow cytometry
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We used a FACSCalibur (BD Biosciences, Billerica, MA) to acquire samples prepared
in FACS staining solution as previously described.[68] After washing once in FACS staining
solution, cells were stained for 30 minutes at 4º C without blocking in FACS staining solution
containing a 1:33 dilution of antibody. When anti-human Fc antibody was used, the anti-Fc
stained sample was washed and re-stained for alternative surface markers before resuspension in FACS buffer for flow cytometer analysis. Measurement of intracellular cytokine
used the same protocol for cell surface staining followed by 20 min. fixation using BD
cytofix/cytoperm kit fixative (BD Biosciences; Cat No. 554714), followed by washing twice in
perm/wash buffer containing 20% FBS and staining with a 1:33 dilution of antibody in
perm/wash buffer. Antibody incubation lasted 30 minutes at 4ºC before samples were washed
in perm/wash buffer and resuspended in FACS staining solution for acquisition. FlowJo v
10.0.5 (Tree Star Inc., Ashland, OR) was used for analysis of flow cytometry data. See Table 2
for antibodies used.

Chromium release assay (CRA)
CRA was performed as previously described.[57] In brief, on Day 21 of T-cell co-culture
on aAPC, the tumor targets (i) EL-4, (ii) NALM-6, and (iii) K562 were loaded with
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Cr for 3

hours, and, after washing, co-cultured with effector T cells for 6 hours at 37º C using a ratio of 5
T cells to 1 target cell.

Abundance and diversity of TCR repertoire
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The direct TCR expression assay (DTEA), as previously reported,[69] was used to
measure the abundance of mRNA transcripts coding for 45 TCR α alleles, 46 TCR β alleles, 13
TCR γ alleles, and 5 TCR δ alleles from RNA obtained on Day 0 (T cells in PBMC before
electroporation) and Day 21 (from T cells after electroporation/ propagation). Day 0 samples
were negatively sorted for CD56 (Miltenyi Biotec, Cambridge, MA; Cat. No. 130-050-401) and
then positively sorted for CD3 (Miltenyi Biotec; Cat. No. 130-050-101). The resulting
CD3+CD56neg T cells (2 to 3 x 106 from each sample) were snap frozen as were 2 x 106 cells
directly harvested at Day 21 of co-culture. RNA was extracted from thawed samples using the
ALLprep DNA/RNA mini kit (Qiagen; Cat. No. 80204).

Statistics

Statistical analysis was performed using Prism v6.0 (Graph Pad Software Inc.).
Student’s t-test (unpaired) was used to perform two sample comparisons. One- or two-way
ANOVA F–test was used to perform group comparisons, and if found significant (p < 0.05); a ttest (unpaired) was undertaken to assess and report differences. Spearman’s nonparametric
correlation was performed on housekeeping gene normalized DTEA transcript counts to assess
the divergence of the TCR repertoire in T cells from an experimental group and autologous Day
0 PBMC. If the Spearman correlation coefficient was greater than or equal to 0.8 (ρ ≥ 0.8)
within the 95% confidence interval of the correlation coefficient, then the two TCR repertoires
were considered to be highly correlated.

Results:
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Figure 5
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Figure 5: Study design to compare ability of chimeric antigen receptor (CAR) ligand (CARL)
versus CD19 TAA on K562 cells for the selective propagation of CAR+ T cells (CART). A)
Artificial antigen presenting cells (aAPC) demonstrated in I) were derived from parental K562
cells following transgene transfer, stable integration, and clonal selection. Each aAPC clone
expresses either CARL, a scFv derived from 2D3 mAb that binds IgG4 exodomain of CAR, or
truncated human CD19. II) CART used to evaluate specificity towards CARL or CD19 are
shown. SB-derived DNA plasmids coding for a panel of CARs were individually electrotransferred into PBMC and recursively stimulated with CD19+ K562 or CARL+ K562 in the
presence of soluble recombinant human IL-2. Each CAR follows a modular design. 19G4CAR
contains the IgG4 scaffold and targets CD19 through the same scFv as 19CAR which lacks
IgG4 scaffold and instead uses CD8α hinge and extracellular domain. GD2G4CAR contains the
IgG4 scaffold and targets GD2. G4CAR contains the IgG4 scaffold, but has no scFv. All CARs
employ of a 2nd generation design containing CD28 and CD3 signaling endodomains. B) On
Day 0, synchronous electroporation of PBMC was undertaken with DNA plasmid coding for SB
transposase (SB11- green) and SB DNA plasmids coding for CAR species (orange). To
achieve outgrowth of T cells stably expressing CARs, the genetically modified cells were cocultured, beginning on Day 1, upon γ-irradiated CD19+ or CARL+ K562 in the presence of 50
IU/mL IL-2. Cytokine was added with stimulation or during media change. Re-stimulation of
CAR with aAPC occurred every 7 days until Day 21. C) Diagram of docking between CARL+
K562 cells and 19G4CAR+ T cells as compared with CD19+ K562 cells with 19G4CAR+ T cells.
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Table 2 Fluorochrome-conjugated antibodies used for flow cytometry.

Antibody

Vendor

Catalogue number

mouse anti-human Fc-PE*

Invitrogen

Cat. No. H10104

CD3-FITC

BD

Cat. No. 349201

CD4-APC

BD

Cat. No. 340443

CD8-PerCP-Cy5.5

BD

Cat. No. 341051

CD28-PerCP-Cy5.5

BD

Cat. No. 337181

CD45RO-APC

BD

Cat. No. 559865

CD62L-PE

BD

Cat. No. 555544

IL-2-APC

BD

Cat. No. 554567

IL-4-PE

BD

Cat. No. 340451

Ifn-γ-FITC

BD

Cat. No. 554700

goat

anti-mouse

Fab- Jackson Immunoresearch

Cat. No. 555415

FITC**

CD19-APC

BD

Cat. No. 555415

*Used to detect CAR containing IgG4 exodomain; ** Used to detect CARL
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Numeric expansion of CAR+ T cells upon K562 cells expressing CARL or CD19

Mouse mAb clone 2D3 was obtained by repeated footpad injections of NSO cells expressing
19G4CAR into BALB/c mice and blocking studies defined the specificity of the mAb to the
human IgG4 exodomain of 19G4CAR.[57] We hypothesized that this mAb may be used to crosslink CAR and activate genetically modified T cells for sustained proliferation. Therefore, the
scFv of 2D3 (designated CARL) was expressed on the cell surface to compare with human
truncated CD19 TAA on K562 cells. The CARL and CD19 transgenes were cloned into DNA
plasmids for co-expression with drug-selection genes between SB transposable elements. The
SB transposon DNA plasmids for 2D3-derived scFv or CD19 were electro-transferred with
SB11 transposase DNA plasmid into K562 cells in separate experiments. Genetically modified
cells were propagated under drug selection from a single cell for homogeneous expression of
CARL (as detected by antibody against mouse Fab) or CD19 (Figure 6A). A comparison of the
γ-irradiated K562-derived aAPC to selectively propagate CART was undertaken following
electroporation (defined as Day 0) of the panel of CAR constructs (Figure 5A.II) into PBMC
using SB system. On Day 1, initial expression of CAR in T cells was evaluated by flow
cytometry using antibody specific for human Fc (Figure 6B). The expression of CARs and
number of total viable T cells were measured weekly for 21 days of co-culture with CD19+ K562
or CARL+ K562 with the following immunoreceptors on T cells; (i) 19G4CAR with specificity for
CD19 and containing the IgG4 exodomain, (ii) 19CAR with specificity for CD19 and absence of
IgG4 exodomain, (iii) G4CAR without scFv, but containing an IgG4 exodomain, and (iv)
GD2G4CAR with specificity for GD2 and containing the IgG4 exodomain. All CAR species
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Figure 6
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Figure 6: Characterization of aAPC and CAR+ T cells. A) CD19 and CARL as SB transposons
were integrated into parental K562 cells using SB11 transposase and clonally expanded for
homogeneous expression of CD19 or CARL. Dot plots depict the expression of CD19 and
CARL on parental K562 and derived clones. The stable expression of CARL is shown using
antibody that detects mouse Fab. B) The expression level of CAR species as determined by
flow cytometry is shown on Days 1 and 21 of co-culture with aAPC. Expression of chimeric
IgG4 revealed CAR expression in all constructs except 19CAR which was determined using an
antibody against human Fc. The percentage of cells in each flow plot quadrant is provided as
an inset. C) The effect of aAPC design on abundance of CAR expression was assessed on
Day 21 by measuring mean fluorescent intensity (MFI) of IgG4 signal by flow cytometry. The
experiments are designated [CAR & aAPC] with unmodified mock electroporated T cells (No
DNA plasmid) used as a control. Each experimental group contained 4 or 5 separate donorderived PBMC. Statistical comparison was undertaken by One-way ANOVA followed by
unpaired t-tests between each experiment (* = p < 0.05).
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contained the same transmembrane and intracellular domains (CD28/CD3ζ) as the 2nd
generation 19G4CAR.[57] The co-cultures of CART with the two types of aAPC were found to
have significantly different amounts of T cells by Day 21 depending on the choice of aAPC (p <
0.05) using two-way ANOVA followed by un-paired t-tests. The 19CAR+ T cells proliferated
upon co-culture with CD19+ K562 and G4CAR+ T cells proliferated upon co-culture with CARL+
K562 in an exponential fashion, whereas 19CAR on CARL+ K562 and G4CAR on CD19+ K562
did not numerically expand (Figure 7A top panel).

These data indicate that, as expected, the CD19 TAA on aAPC selectively supports the
outgrowth of CD19-specific CART. Furthermore, they demonstrate that CARL can activate T
cells to proliferate that contain a CAR species with an IgG4 exodomain. Next, the ability of
CD19+ K562 and CARL+ K562 were assessed for ability to sustain the proliferation of T cells
expressing 19G4CAR to evaluate how two modes of crosslinking (Figure 5C) can activate T
cells. There were no significant differences in the accumulated number of viable T cells on Day
21 of co-culture based on the type of aAPC used (Figure 7A bottom panel), the expression of
CAR as a percent of the population (Figure 7B bottom panel), or the mean fluorescence
intensity (MFI). A trend (p = 0.09) towards a difference in MFI of CAR expression resulting from
aAPC employed to expand 19G4CAR was noted (Figure 6C). There were no significant
differences (Figure 7C & D) between the two aAPC types for propagating 19G4CAR+ T cells
co-expressing cell-surface proteins associated with memory phenotype (p = 0.82),[70] or other
co-receptors (p = 0.26), as well as the specific lysis by 19G4CAR+ T cells (p = 0.16). Therefore,
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Figure 7
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Figure 7: Comparison of CAR+ T cells propagated on CD19+ or CARL+ aAPC. A) Total inferred
T-cell number and B) CAR (IgG4) expression for each CART was measured every 7 days for 5
donors. Top panel: 19CAR+ or G4CAR+ T cells were numerically expanded on either CD19+ or
CARL+ aAPC. Bottom panel: 19G4CAR+ T cells were propagated on either CD19+ or CARL+
aAPC. C) After 21 days of co-culture on CD19+ or CARL+ aAPC, 19G4CAR+ T cells from 5
donors were assessed for expression of markers associated with memory (top panel) or T cell
co-receptors (bottom panel). D) Specific killing by electroporated/propagated T cells expressing
19CAR, G4CAR, and 19G4CAR, by CRA at a ratio of 5 effectors to 1 target. The tumor targets
were EL-4 (murine thymoma- GD2+, CD19neg), NALM-6 (human B cell ALL- GD2neg, CD19+),
and K562 (a human CML- GD2neg, CD19neg). Up to 5 donors were tested in 4 independent
experiments. ns- No significance, * = p<0.05, *** = p<0.001
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CD19-specific CAR+ T cells can be propagated in similar quantity and quality by K562-derived
aAPC expressing CAR or CD19.
CARL+ K562 can numerically expand CAR+ T cells independent of specificity

The 2D3-derived scFv on aAPC was evaluated for ability to propagate not just CD19specific T cells, but CAR+ T cells of alternative specificities. The CD19 and GD2

[71]

TAAs are

not present on parental K562 cells to propagate T cells expressing GD2G4CAR, 19G4CAR,
and G4CAR. Nonetheless, T cells bearing these three CARs numerically expanded on CARL+
K562. The number of total viable T cells on Day 21 of co-culture with CARL+ K562 cells did not
significantly differ between 19G4CAR, G4CAR, and GD2G4CAR (p = 0.16, Figure 8A).
Similarly, the percentage of each CAR expressed on T cells at Day 21 did not significantly differ
among the three populations of genetically modified T cells (p = 0.68, Figure 8B). Finally, the
electroporated and propagated T cells exhibited specific lysis of CD19 and GD2 TAAs
recognized by CD19-specific and GD2-specific CARs. EL-4 cells, previously reported to
express GD2, [66] were specifically killed by GD2G4CAR+ T cells and not with T cells expressing
G4CAR or 19G4CAR. As anticipated, CD19+ NALM-6 cells were targeted by T cells expressing
19G4CAR (Figure 8C). In summary, genetically modified T cells can be selectively propagated
by CARL+ K562 cells resulting in T cells that retain specificity for TAA and stable expression of
CAR.
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Figure 8
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Figure 8: Numeric expansion of CAR+ T cells using CARL+ aAPC. A) Total inferred T-cell
number and B) CAR (IgG4) expression for each CART was measured every 7 days from 4 to 5
donors for 21 days of co-culture on aAPC. The differences between Day 21 total T-cell number
and percent CAR expression was assessed using One-way ANOVA. C) The specific killing by
panel of T cells expressing GD2G4CAR, 19G4CAR, and G4CAR, were tested using CRA at a
ratio of 5 effectors to 1 target. The targets were EL-4 (GD2+, CD19neg), NALM-6 (GD2neg,
CD19+), and parental K562 (GD2neg, CD19neg). Two-way ANOVA followed by unpaired t-tests
was performed for 4 to 5 donors tested in 4 independent tests on Day 21 of co-culture on
aAPC. ns- No significance, * = p<0.05.
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The choice of aAPC does not skew the TCR repertoire for numerically expanded CART

Each T cell in peripheral blood bears a distinct pair of αβ or γδ TCRs which can be
analyzed using the direct TCR expression assay (DTEA) to determine the abundance of TCR
chains. This assay was employed to determine whether CARL+ or CD19+ K562 influenced the
distribution of TCR alleles after 21 days co-culture on aAPC. TCR variants were assayed on
the nCounter Analysis System using a set of 111 TCR α, β, γ, and δ transcripts.[68,

69]

By

measuring the distribution of TCR alleles we could determine if the aAPC design preferentially
supported the numeric expansion of some, but not all genetically modified T cells. The starting
TCR distribution of T cells on Day 0 was ranked from the most to least frequent TCR usage
and the rank order compared for T cells harvested on Day 21 of co-culture with aAPC (Figure
9A). This revealed no apparent monoclonal or oligoclonal outgrowth of electroporated T cells
propagated on CARL+ or CD19+ K562 cells. The ranks of TCR frequencies on Day 0 and Day
21 from each experiment were compared using Spearman’s rank correlation test and found to
significantly correlate (p < 0.0001; Table 3). The statistical comparison of TCR abundance and
type from Day 0 and 21 indicated that all correlation coefficients (ρ) had values greater than 0.8
within the 95% confidence interval of ρ which is consistent with a strong correlation, indicating
no change in TCR frequency. The measurement of TCR abundance demonstrates that CARL
or TAA on aAPC do not skew the outgrowth of sub-populations of propagated T cells, but
rather that both 2D3-derived scFv and CD19 on K562 cells can sustain the outgrowth of CAR+
T cells that maintain a polyclonal repertoire.
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Figure 9

Figure 9: Comparison of TCR repertoire changes induced by CAR-mediated expansion on
aAPC. A) TCR repertoire was measured for 111 TCR α, β, γ, and δ alleles using DTEA.

[69]

TCR abundance was organized from the most to the least frequently occurring transcripts
based on sorted CD3+CD56neg cells from Day 0. The set is visually represented next to TCR
repertoire expressed by T cells at Day 21 of co-culture on CARL+ K562 cells and CD19+ K562
cells. Analysis was performed on 2 donors and a representative plot of one donor is shown.
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Table 3 Comparison of TCR abundance harvested from T cells before versus after
propagation on aAPC*

Day

0

0

19G4CAR &
CARL+ K562
G4CAR &
21

21

19G4CAR & G4CAR &

GD2G4CAR &

19G4CAR &

+
CARL+ K562 CARL K562

CARL+ K562

CD19+ K562

0.748

0.857

0.867

0.912

(0.65-0.82)

(0.80-0.90)

(0.81-0.91)

(0.87-0.94)

0.805

0.706

0.734

(0.72-0.86)

(0.59-0.79)

(0.63-0.81)

0.752
(0.65-0.83)
0.899
(0.85-0.93)

0.71

0.816

0.839

(0.61-0.79)

(0.74-0.87)

(0.77-0.89)

GD2G4CAR & 0.825
CARL+ K562
(0.75-0.88)

0.72

0.801

0.881

(0.61-0.80)

(0.72-0.86)

(0.83-0.92)

19G4CAR &

0.69

0.887

0.808

(0.57-0.78)

(0.84-0.92)

(0.73-0.87)

CARL+ K562

CD19+ K562

0.916
(0.87-0.94)

*Analysis DTEA data from two donors was normalized using housekeeping genes and
assessed using Spearman correlation coefficient to compare distributions of TCR usage for two
donors. The upper right of the table contains the correlation between experimental groups for
one donor. The lower left of the table contains the second donor subjected to the same
analysis. Each cell in the table contains the Spearman correlation coefficient (ρ) and within the
brackets the 95% confidence interval. (A strong correlation is considered to be ρ ≥ 0.8.)
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Discussion
This study demonstrates that a ligand directed against a conserved extracellular domain
on CARs can function to numerically expand CART while preserving redirected specificity of
genetically modified T cells for TAA. This differs from other methods to select or sort for CART
such as magnetic sorting,

[37]

selection with cytotoxic drug,

[56]

or TAA-mediated numeric

expansion. A recent report demonstrated antigen-independent CAR-mediated T-cell activation
using antibody binding to an extracellular Myc-tag of ErbB2-specific T cells.[72] Our study differs
as CARL recognizes a determinant native to an extracellular scaffold to induce proliferation of
CART. This provides an apparent advantage, as the use of epitope tags may alter antigen
recognition or increase immunogenicity. Our data demonstrate that a mAb-derived scFv
sequence directed against conserved extracellular CAR domains can be used for cross-linking,
activation, and propagation of CAR species on genetically modified T cells.[50-52] Thus, CARLmediated numeric expansion of CART will be useful to laboratories seeking to augment the
selective outgrowth of CART within a tissue culture environment after gene transfer.

A benefit of our approach is that one CARL design could functionally substitutes for
multiple TAAs. Specifically, the CARL in this report enables K562 cells to function as aAPC to
propagate T cells expressing a panel of CARs to specifically lyse tumor cells expressing
multiple TAAs. Alternatively, our technology allows for CARs to be designed which impart no
specificity. This was demonstrated here as a proof-of-concept with G4CAR activating T cells to
proliferate during co-culture with CARL+ K562 cells without ligating endogenous CD3. Implicit in
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this finding is that any T cell bearing an introduced CAR, or other immunoreceptor containing
the CARL-binding domain, may be propagated upon cross-linking by CARL.

Recent studies have demonstrated that reducing the length of an IgG4 exodomain
improved cytokine secretion, cytotoxicity, and proliferation of ROR1-specific CART

[73]

and

removal of IgG1 scaffold from a CAR appeared to improve killing of CD22+ targets.[74] These
improvements in potency support modifying the scFv distance from the T-cell membrane to
enable a candidate CAR design to provide a fully-competent T-cell activation signal. The
identification of the peptide recognized by 2D3-derived scFv is ongoing, and may enable us to
alter the length of the extracellular domain to tune CAR+ T cells for optimal activation by TAA
while preserving the ability of CARL to propagate genetically modified T cells.

One measure of redirected specificity is the ability of CAR to mediate T-cell killing of
TAA+ targets. The cytotoxicity of CARL-propagated CART appears to be moderately reduced
based on prior publications.[64,

75]

This may be accounted by the design of the CARL+ and

CD19+ aAPC, which were not engineered to express costimulatory molecules such as CD86,
CD137L and membrane-bound IL-15, as are present on aAPC (designated clone 4) we
previously used to generate CD19-specific 19G4CAR+ T cells.[49] Furthermore, we used aAPC
clone 4 in the presence of soluble recombinant IL-2 and IL-21 whereas CARL+ K562 cells were
co-cultured with genetically modified T cells with only IL-2. Future studies will help elucidate the
effect of costimulation on CART performance.

It is possible that the aAPC used to activate CAR may selectively propagate a subpopulation of genetically modified T cells over the co-culture period. However, we observed
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that both CARL+ and CD19+ K562 cells numerically expanded T cells bearing a similar
percentage expression and density of CAR, a comparable immunophenotype. In addition, there
were no significant differences in TCR repertoire expression and abundance before versus
after propagation on aAPC indicating that the starting population of T cells matched the
population present at the end of the co-culture period. These findings justify investigating
whether CARL+ aAPC might be used to generate CART for human application. Furthermore, it
is our expectation that expression of CARL on a single source of clinical-grade aAPC can be
used to generate panels of CAR+ T cells, overcoming the current need to produce panels of
aAPC with each expressing a given TAA for a given specificity of CART.

In summary, we report the development of an aAPC based on a CAR-specific mAb for
the CAR-mediated propagation of CAR+ T cells with multiple specificities.
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CHAPTER 3: Establishing anti-thymidine resistance in T cells
INTRODUCTION

Certain chemotherapies used to treat cancer are able to activate the immune system.
One of the ways chemotherapy does this is by causing the cancer to die in a way that activates
the immune system. This is called immunogenic cell death.[76] Integrating immunogenic cell
death with newer forms of immunotherapy, such as adoptive transfer of T cells, could
potentially improve patient outcomes by improving the immunologic response of adoptively
transferred T cells towards cancer.[77, 78] However, the toxicity and immunosuppressive nature
of many of these chemotherapies prevents the concurrent use of chemotherapy with adoptive
transfer of T cells. To utilize the immunogenicity of chemotherapy without affecting the efficacy
of adoptively transferred T cells there are two strategies: 1) adoptively transfer T cells following
the clearance of each dose of chemotherapy, or 2) adoptively transfer T cells geneticallymodified to resist chemotherapy-induced toxicity before the administration of multiple rounds of
chemotherapy.

Genetically-modifying T cells to resist toxicity from chemotherapy appears to be a
desirable strategy, but has presented a technological challenge to the field. The depletion of T
cells by chemotherapy is most apparent in the aftermath of allogeneic hematopoietic stem cell
transplant (HSCT) where the conditioning chemotherapy and subsequent immunosuppressive
chemotherapy, used to prevent graft versus host disease, prevents both anti-tumor[22] and antiviral[27] immunity mediated by T cells. Various groups have attempted to address this issue by
knocking down

[79]

or inserting a gene which confers resistance
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[80]

to the commonly used

immunosuppressive drugs tacrolimus and cyclosporine. Genetic-modification of T cells to resist
other immunosuppressive drugs have followed including temsirolimus,
mofetil,

[46]

[81]

mycophenolate

and immunosuppressive doses of methotrexate (MTX).[82] These modifications have

been made using mutated human proteins (muteins) resistant to higher doses of the toxic
chemotherapy.

Unfortunately,

only

one

mutein

has

been

described

to

resist

a

chemotherapeutic agent typically used outside of the HSCT setting. That is resistance to
temozolomide for concurrent use with T cell therapy in the treatment of brain cancer.[83]

Muteins resistant to chemotherapeutics targeting the most common cancers - lung,
breast, colon, and pancreas,[84] – are lacking. In seeking a mutein for these cancers we
considered leading candidate drugs which were non-genotoxic. Hence, the chemotherapy
resistant T cell would receive no genotoxic insult and would not be at an increased
susceptibility for malignant transformation. Anti-thymidylates (AThys) appeared to be the
optimal candidate as the AThy 5-fluorouracil (5-FU) is used to treat breast, colon, and
pancreatic cancer, [85] and lung cancer is treated with the AThy pemetrexed (Pem).[86] All AThys
inhibit the synthesis of thymidine from uridine by blocking the activity of thymidylate synthase
(TYMS) and/ or co-enzyme dihydrofolate reductase (DHFR) (See Figure 10A). The inhibited
synthesis of thymidine prevents DNA synthesis, and ultimately leads to death in rapidly
replicating cells such as activated T cells or cancer cells.[85, 86] Thus, AThy resistance (AThyR)
conferred by a mutein TYMS and DHFR should permit resistance to 5-FU and Pem, and this
was shown in murine bone marrow cells.[87, 88] Here, we propose AThyR is feasible in human T
cells using a mutein of DHFR resistant to MTX - DHFRFS, [89] in combination with a mutein of
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TYMS. The human mutein of TYMS - TYMSSS – has not yet been described outside of the
bacterial system in which it was developed.[90]
To test the ability of DHFRFS and TYMSSS to resist toxic levels of AThys, selective
outgrowth assays were developed where AThyR+ T cells co-expressed fluorescent proteins
that were used to track improved survival by flow cytometry. We find that combining DHFRFS
with TYMSSS confers survival advantages to AThyR+ T cells in toxic concentrations of MTX, 5FU, and Pem, as expected. It is noted that TYMSSS also enhances the survival advantage of
DHFRFS to MTX, likely through improved resistance of TYMSSS towards the anti-TYMS action
of MTX.[86] Furthermore, we discover that a known biochemical phenomenon in which TYMS
auto-regulates expression of TYMS[91] and DHFR auto-regulates expression of DHFR[92] is coopted by TYMSSS and DHFRFS. Our findings show that DHFRFS and its cis-expressed
fluorescent protein are up-regulated by increasing doses of MTX and that TYMS cis-expressed
fluorescence proteins are down-regulated at the same concentration of MTX. These findings
further elucidate unknown aspects of the auto-regulatory biochemical pathway and
demonstrate that AThyRs DHFRFS and TYMSSS can be used to increase or decrease the
expression of cis transgene in a drug dependent manner. The ability of AThyRs to enhance
survival in the presence of chemotherapy and inducibly change cis transgene makes these
transgenes desirable for selecting intracellular transgenes, such as suicide genes. Thus,
DHFRFS was used to select for the suicide gene inducible caspase 9 (iC9)

[35, 93]

in vitro as a

demonstration of the utility of AThyRs in future studies involving adoptive T cell transfer.

MATERIALS AND METHODS:
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Cells and culture conditions:

Cells: Peripheral blood mononuclear cells (PBMC) derived from healthy donors at the Gulf
Coast Regional Blood Bank or MDACC Blood Bank, both in Houston, Texas, was subjected to
density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Biosciences,
Piscataway Township, NJ; Cat No. 17-1440-02). PBMC were washed once in CliniMACS Plus
PBS/EDTA buffer (Miltenyi Biotec, Gladbach, Germany, Cat. No. 130-070-525) and twice in
Dulbecco’s PBS (D-PBS) (Sigma-Aldrich, St. Louis, Missouri, Cat. No. D8537) before resting in
complete media (CM) made of RPMI 1640 (Thermo Scientific Hyclone, Bridgewater, NJ; Cat.
No. SH30096.01), 10% heat-inactivated fetal bovine serum (FBS -Thermo Scientific Hyclone,
Cat. No. SH30070.03), and 2 mM GlutaMAX supplement (Life Technologies, Grand Island, NY;
Cat. No. 35050061). Alternatively, PBMC were frozen using a prepared mixture of 50% heatinactivated FBS, 40% RPMI 1640, and 10% DMSO (Sigma-Aldrich, PA; Cat. No. D2650) freeze media (FM) at 4 X 107 cells/ mL. The use of rested or frozen PBMC is outlined in each
experiment. The Jurkat cell line, a human T cell acute lymphoblastic leukemia (American Type
Culture Collection, Manassas, VA, Cat. No. TIB-152) was used and maintained in CM. The
identity of this cell line was assured by short tandem repeat DNA fingerprinting performed by
MDACC Cancer Center Support Grant Characterized Cell Line Core. Activating and
propagating cells (AaPC) were used to stimulate T cells. The AaPC cell line K562 clone.4,
expressing CD86, CD137, CD64, along with membrane bound IL-15, was modified to present
OKT3 antibody for the polyclonal stimulation of T cells, as previously described.[94] For the
propagation of chimeric antigen receptor (CAR)+ T cells, the AaPC CARL+ K562[95] was utilized.
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All AaPC were rapidly thawed in a 37º C water bath and washed twice before stimulation of T
cells.[94]

Jurkat and AaPC were tested for the presence of mycoplasma before use. Cell

counting was accomplished in a mixture of 0.1 % Trypan Blue (Sigma-Aldrich, T8154) with the
Cellometer K2 Image Cyotmeter (Nexcelom, Lawrence, MA).

Chemical and biological agents:

Stimulation via CD3 and CD28 was achieved by the addition of 30 ng/mL OKT3 antibody
(eBioscience, San Diego, CA, Cat. No. 16-0037-85), 100 ng/ mL anti-CD28 antibody (EMD
Millipore, Temecula, CA, Cat. No. CBL517). T cell stimulation included recombinant human IL-2
(Proleukin, Prometheus Labs, San Diego, CA). When indicated, the following drugs were used:
5-FU, MTX, pemetrexed, raltitrexed, G418, and AP20187. Further information regarding each
drug is given in Table 4.

DNA expression plasmids:

DNA plasmids for testing AThyR transgenes were generated using the previously described
DNA plasmid G4CAR as a backbone.[95] Commercially synthesized FLAG-DHFRFS, codon
optimized (CoOp) DHFRFS, FLAG-TYMSSS, and CoOp TYMSSS DNA (Life Technologies, Gene
Art), and neomycin resistance gene (NeoR) DNA product were cleaved by NheI and ApaI.
Reporter genes mCherry with N-terminus SV40 nuclear localization sequence (RFP), inducible
suicide gene CoOp iC9 (both produced by GeneArt), and enhanced green fluorescent protein
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Table 4 Chemical Agents

Agent

Manufacturer

ID No.

5-fluorouracil

APP Pharmaceuticals, Schaumburg, IL

NDC 63323-117-10

Methotrexate

Hospira, Lake Forest, IL

NDC 61703-350-38

Pemetrexed

Lilly, Indianapolis, IN

NDC 0002-7640-01

Raltitrexed

Abcam Biochemicals, Cambridge, MA

Ab142974

G418

Invivogen, San Diego, CA

Ant-gn-1

AP20187

Clontech, Mountain View, CA

635060
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(eGFP) DNA were digested by ApaI and KpnI. The G4CAR backbone was restriction enzyme
digested by NheI and KpnI. The G4CAR backbone was ligated with NheI and ApaI digested
fragments and ApaI and KpnI digested fragments in a three component ligation. Enzyme
digestion locations of NheI, KpnI, and ApaI are shown in Figure 10B. The drug resistant
component [DHFRFS, TYMSSS, or NeoR] was permutated with the transgenes [RFP, CoOp iC9,
and GFP] to make the following DNA plasmids: FLAG-DHFRFS-2A-eGFP pSBSO (DG), FLAGCoOp DHFRFS-2A-eGFP pSBSO (CoOp DG) FLAG-TYMSSS-2A-GFP pSBSO (TSG), FLAGCoOp TYMSSS-2A-GFP pSBSO (CoOp TSG), FLAG-TYMSSS-2A-RFP pSBSO (TSR), NeoR2A-GFP pSBSO (NRG), FLAG-DHFRFS-2A-iC9 pSBSO (DFSiC9). Codon optimization of
DHFRFS and TYMSSS DNA was performed to avoid the mRNA transcript from being bound by
DHFR and TYMS proteins, respectively. Known RNA binding motifs of DHFR and TYMS
mRNA are recognized by DHFR[92] and TYMS[96], respectively. Codons of DHFRFS and TYMSSS
were altered as much as possible while maintaining the amino acid sequence of each protein in
order to avoid protein binding of the mRNA transcript. Previously described CD19-specific
chimeric antigen receptor (CAR)[95] was utilized without modification.

Myc-ffLuc-NeoR pSBSO (NRF) was constructed using the backbone of CD19-2A-Neo
pSBSO[95] isolated after restriction digestion with NheI and SpeI. NheI and SpeI digested Mycfirefly Luciferase (ffLuc) insert was ligated to CD19-2A-Neo backbone followed by digestion of
the ligation product with SpeI and EcoRV. SpeI and EcoRV digested NeoR fragments were
then ligated to the digested backbone to yield NRF. All constructs contain Sleeping Beauty
(SB) indirect/ direct repeat (IR/DR) sites to induce genomic integration in the presence of SB
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Table 5 Synthetic DNA/ protein sequences

FLAG-

atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaagacgacgat

dmDHFR

gataaggacgtcgttggttcgctaaactgcatcgtcgctgtgtcccagaacatgggcatcggcaagaacggg
gacttcccctggccaccgctcaggaatgaatccagatatttccagagaatgaccacaacctcttcagtagaa
ggtaaacagaatctggtgattatgggtaagaagacctggttctccattcctgagaagaatcgacctttaaagg
gtagaattaatttagttctcagcagagaactcaaggaacctccacaaggagctcattttctttccagaagtctag
atgatgccttaaaacttactgaacaaccagaattagcaaataaagtagacatggtctggatagttggtggcag
ttctgtttataaggaagccatgaatcacccaggccatcttaaactatttgtgacaaggatcatgcaagactttga
aagtgacacgttttttccagaaattgatttggagaaatataaacttctgccagaatacccaggtgttctctctgatg
tccaggaggagaaaggcattaagtacaaatttgaagtatatgagaagaatgat

FLAG-CoOp

atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaggacgatgatg

dmDHFR

acaaagacgtcgtgggcagcctgaactgcatcgtggccgtgtcccagaacatgggcatcggcaagaacgg
cgacttcccctggccccctctgcggaacgagagccggtacttccagcggatgaccaccaccagcagcgtg
gaaggcaagcagaacctcgtgatcatgggcaagaaaacctggttcagcatccccgagaagaaccggccc
ctgaagggccggatcaacctggtgctgagcagagagctgaaagagccccctcagggcgcccacttcctga
gcagatctctggacgacgccctgaagctgaccgagcagccagagctggccaacaaggtggacatggtgtg
gatcgtgggcggcagctccgtgtacaaagaagccatgaaccaccctggccacctgaaactgttcgttaccc
gtataatgcaggatttcgagagcgataccttcttccccgagatcgacctggaaaagtacaagctgcttcccga
gtaccccggcgtgctgtccgatgtgcaggaagagaagggcatcaagtacaagttcgaggtgtacgagaag
aatgac
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FLAG-

atgtatccgtacgacgtaccagactacgcatatccgtacgacgtaccagactacgcagacgtccctgtggcc

dmTYMS

ggctcggagctgccgcgccggcccttgccccccgccgcacaggagcgggacgccgagccgcgtccgcc
gcacggggagctgcagtacctggggcagatccaacacatcctccgctgcggcgtcaggaaggacgaccg
ctcgagcaccggcaccctgtcggtattcggcatgcaggcgcgctacagcctgagagatgaattccctctgctg
acaaccaaacgtgtgttctggaagggtgttttggaggagttgctgtggtttatcaagggatccacaaatgctaa
agagctgtcttccaagggagtgaaaatctgggatgccaatggatcccgagactttttggacagcctgggattct
ccaccagagaagaaggggacttgggaccagtttatggcttccagtggaggcattttggggcagaatacaga
gatatggaatcagattattcaggacagggagttgaccaactgcaaagagtgattgacaccatcaaaaccaa
ccctgacgacagaagaatcatcatgtgcgcttggaatccaagagatcttcctctgatggcgctgcctccatgc
catgccctctgccagttctatgtggtgaacagtgagctgtcctgccagctgtaccagagatcgggagacatgg
gcctcggtgtgcctttcaacatcgccagctacgccctgctcacgtacatgattgcgcacatcacgggcctgaa
gccaggtgactttatacacactttgggagatgcacatatttacctgaatcacatcgagccactgaaaattcagc
ttcagcgagaacccagacctttcccaaagctcaggattcttcgaaaagttgagaaaattgatgacttcaaagc
tgaagactttcagattgaagggtacaatccgcatccaactattaaaatggaaatggctgtt

FLAG-CoOp-

atggactacaaggacgacgacgacaaggattacaaggatgatgatgataaggactataaggacgatgatg

dmTYMS

acaaagacgtccccgtggccggcagcgagctgcctagaaggcctctgcctcctgccgctcaggaaaggga
cgccgaacctagacctcctcacggcgagctgcagtacctgggccagatccagcacatcctgagatgcggc
gtgcggaaggacgacagaagcagcacaggcaccctgagcgtgttcggaatgcaggccagatacagcct
gcgggacgagttccctctgctgaccaccaagcgggtgttctggaagggcgtgctggaagaactgctgtggtt
catcaagggcagcaccaacgccaaagagctgagcagcaagggcgtgaagatctgggacgccaacggc
agcagagacttcctggacagcctgggcttcagcaccagagaggaaggcgatctgggtcccgtgtacgggtt
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tcaatggcggcacttcggcgccgagtatcgggacatggagagcgactacagcggccagggcgtggacca
gctgcagagagtgatcgacaccatcaagaccaaccccgacgaccggcggatcatcatgtgcgcctggaa
ccccagagatctgcccctgatggccctgcctccatgtcacgccctgtgccagttctacgtcgtgaactccgagc
tgagctgccagctgtaccagcggagcggcgatatgggactgggcgtgcccttcaatatcgccagctacgcc
ctgctgacctacatgatcgcccacatcaccggcctgaagcccggcgactttatccacaccctgggcgacgcc
catatctacctgaaccacatcgagcccctgaagattcagctgcagcgcgagcccagacccttcccaaagct
gcggatcctgcggaaggtggaaaagatcgacgacttcaaggccgaggacttccagatcgagggctacaa
cccccaccccacaatcaagatggaaatggccgtg
eGFP forward

5` cccgggcccggcgccatgccacctcctcgcctcctcttc 3`

eGFP reverse

5` ggtacccttgtacagctcgtccatgccgagagtgatcccggcggcggtcac 3`

NeoR forward

5’ gctagcacatgtgccaccatgattgaacaagatggattgcacgcaggttctccggccgcttgg 3`

Neo R reverse 5’
aagcttccgcggccctctccgctaccgaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaat
c 3`
NLS

MAPKKKRKVGIHRGVP
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transposase. Each transgene is promoted using elongation factor 1 alpha (EF1-α) promoter.
Cartoon representations of frequently used constructs can be seen in Figure 10 B and Figure
17A. Select DNA and protein sequences can be found in Table 5.

Genetic Modification and Propagation of Cells:

The Amaxa Nucleofector® II (Lonza, Allendale, NJ) was used to electroporate both
Jurkat and human PBMC. Electroporation of Jurkat cells utilized a modified buffer[97] containing
5 mM KCl, 15 mM MgCl2, 120 mM Na2HPO4/NaH2PO4, pH 7.2, and 50 mM DMSO, where 106
Jurkat cells per cuvette were electroporated using program T-14 before immediate transfer to
CM. The addition of drug occurred 48 hours after electroporation and cell culture remained
undisturbed until sampling for gene expression on days 10-12 post electroporation. Human
PBMC electroporation followed a previously described protocol.[95] Briefly, 1 to 2 X 107 thawed
PBMC per cuvette were electroporated in Amaxa T cell Nucleofector solution (Lonza
Biosciences; Cat No. VPA-1002) using program U14. On the following day, PBMC were
stimulated in fresh CM with AaPC at a ratio of 1: 1 including 50 IU/ mL IL-2, unless otherwise
noted. The cellular co-culture concentration of 106 cells/ mL was maintained at each
stimulation, and PBMC derived T cells were re-stimulated every 7 days using the same
concentrations. IL-2 was added when media was changed between stimulations. Drug
treatment initiated 48 hours after co-culture began and continued until day 14. Drug was only
added with fresh CM.

Western blot:
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106 T cells were centrifuged from culture, supernatant aspirated, and the pellet rapidly
frozen in liquid nitrogen. Whole-cell extracts were harvested using 50 mM Tris, 150 mM NaCl, 1
mM EDTA, 1% NP-40, 0.5% deoxycholate, 1mM phenylmethylsulfonyl fluoride, 150 mM pnitrophenyl phosphate and 0.3 µM Aprotinin, pH 7.4. Proteins were separated by SDS-PAGE in
reducing conditions and analyzed using specific primary antibodies indicated in Table
6. Detection was performed using an enhanced chemiluminescence detection system.

Flow cytometry:
Cultured cells were resuspended, and washed once in FACS staining solution.[95] If
transgene expression alone was sought, the specimen was then analyzed on a flow cytometer.
The BD LSRFortessa (BD Biosciences) was used to analyze RFP expression; otherwise, BD
FACSCalibur (BD Biosciences) was used. Surface antibody staining was performed in FACS
staining solution with fluorochrome-conjugated antibodies at 4º C for at least 30 minutes.
Antibody targets, concentrations, and manufacturers are listed in Table 7. Analysis of flow
cytometry data utilized FlowJo v 10.0.5 (Tree Star Inc., Ashland, OR).

Luciferase assay:

Cultured T cells were tested for the persistence of ffLuc transgene by the cleavage of Dluciferin (Perkin Elmer, Waltham, MA, Cat. No. 122796). Resuspended cells were plated and
washed once in D-PBS before testing in a D-PBS solution of D-luciferin at 0.14 mg/ mL. After
incubation at 37 º C for 10 min, the plate was analyzed on a TopCount NXT Luminescence
Counter (Perkin Elmer).
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Table 6 Western Blot Antibodies

Antibody

Manufacturer

Cat. No.

Dilution

Actin

Sigma

A2228

1:10000

Hsp-70

Santa Cruz Biotechnology, Dallas, TX

SC-24

1:5000

DHFR

Santa Cruz Biotechnology

SC-377091

1: 1000

TYMS

Millipore

MAB4130

1: 1000

Myc Tag

CST

2276S

1: 1000

DYKDDDDK Tag

Pierce

MA1-91878

1: 1000
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Table 7 Flow Cytometry Antibodies

Antibody

Manufacturer

Cat. No.

Dilution

CD3-APC

BD Pharmingen

340661

1:33

CD3-PerCP-Cy5.5

BD Pharmingen

340949

1:33

CD4 FITC

BD Pharmingen

340133

1:33

CD4 -PE

BD Pharmingen

347327

1:33

CD4-PerCP-Cy5.5

BD Pharmingen

341645

1:33

CD8-APC

BD Pharmingen

340659

1:33

Annexin V-PE

BD Pharmingen

556422

1:20

7-AAD

BD Pharmingen

559925

1:20

Propidium Iodide

BD Pharmingen

556463

Human Fc-PE

Invitrogen

H10104

1:40

Myc- AF488

MBL

M047-A48

1:33

FLAG-AF647

Cell Signaling

3916S

1:33
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Chromium Release Assay:

Antigen specific cytotoxicity was assessed by chromium release assay (CRA). This
assay was previously described.[95] Briefly, antigen positive CD19+ EL-4 were compared to
antigen negative CD19neg EL-4 after each cell line was loaded with

51

Cr for 3 hours and

subsequently incubated with CD19-specific CAR+ T cells at a 1 target : 5 effector cell ratio for 6
hours. Release of 51Cr from cell lysis was assessed by the TopCount NXT scintillation counter.

Statistical Analysis:

Statistical analysis and graphical representation of data was achieved using Prism v6.0
(Graph Pad Software Inc., La Jolla, Ca). Experiments of more than one variable were analyzed
by multivariate analysis: Two-Way ANOVA was used when appropriate with Sidak’s multiple
comparison test, One-Way ANOVA was used when appropriate with Tukey’s or Dunnett’s
multiple comparison tests as applicable, non-Gaussian distributions were assessed by the
Kruskall-Wallis test followed by Dunn’s multiple comparison test. Single variable tests
(experimental vs. control) were made using the Mann-Whitney test. Statistical significance was
designated as α < 0.05.

RESULTS:

Testing AThyR transgene selection in Jurkats.
Jonnalagadda et. al recently developed DHFRFS+ T cells resistant to MTX with in vitro
and in vivo applications.[46,

82]

The studies focused on demonstrating that DHFRFS+ T cells

continue to survive and function in a moderate dose of MTX used post-HSCT. We continued
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using DHFRFS to determine whether T cells can be genetically-modified to resist toxic doses of
AThys used in the initial treatment of malignancy. For this purpose, a combination of mutein
human TYMS with DHFRFS was sought. 5-FU resistant TYMS muteins previously identified
within a bacterial culture system[90] were tested in human cells (not shown) and TYMSSS was
chosen for further study.

To test the enhanced survival of each AThyR, constructs individually expressing
DHFRFS, TYMSSS, and NeoR were ligated into the same backbone containing Sleeping Beauty
(SB) transposable elements upstream of eGFP (Figure 10B). eGFP was used to track the
predominance of surviving genetically-modified T cells. Jurkat cells were co-electroporated with
each construct and SB11 transposase

[57]

which mediated genomic integration of each

construct. Cytotoxic drugs were added two days after electroporation. Jurkat were assessed for
eGFP expression in viable cells by propidium iodide (PI) exclusion on day 10-12 (Figure 10C).
Increased percentage expression of eGFP was sought as a measure for transgene selection in
the presence of drug. Overall survival and mean fluorescence intensity (MFI) of eGFP are also
given in Figure 11AI and AII, respectively. Overall, we demonstrate that DHFRFS has much
better selection than the traditional drug-resistance transgene NeoR. We also demonstrate that
TYMSSS has no independent capacity to enhance Jurkat survival.
More specifically, we found that DHFRFS confers resistance to MTX at concentrations
range of 0.01-0.5 µM, and codon optimization of DHFRFS enhanced the drug resistance range
of CoOp DHFRFS to 0.01-1 µM (Figure 10C). Codon optimization removed potential
endogenous DHFR binding to the DHFRFS mRNA as well as possible micro RNA binding
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domains.[92] Notably, gating on eGFP+ cells demonstrated that DHFRFS constructs lead to a
MTX dependent increase in eGFP MFI. Hence, eGFP expression within a single cell increased
based on the addition of MTX. This finding occurred independent of mRNA regulation until 5
µM MTX where endogenous codon DHFRFS expression significantly decreased compared to
CoOp DHFRFS (p< 0.0001) (Figure 11A-II). Drug inducible transgene expression is a rare
phenomenon. This phenomenon, although rare, is not novel and the capacity of DHFR to
increase cis-expressed eGFP in an MTX dependent manner was previously described for
native DHFR. However, this was attributed to MTX binding DHFR, DHFR releasing DHFR
mRNA, and free DHFR mRNA leading to increased translation of DHFR protein.[98] Here we
note that the phenomenon also occurs with MTX resistant DHFRFS, and with DHFRFS occurs
independent of mRNA regulation from 0.01 – 1 µM MTX. Hence, we postulate the regulation of
DHFR expression occurs partially through an mRNA independent mechanism, which has not
been described to our knowledge. We further explore this mechanism in later sections
As noted, there was no drug selective advantage for TYMSSS expressing Jurkat when
tested with 5-FU (Figure 10C). Native codon TYMSSS had no expression advantage over No
DNA Jurkat at any concentration of 5-FU. Further analysis of eGFP+ cells for eGFP MFI
revealed that TYMSSS expressed at a lower eGFP MFI compared to CoOp TYMSSS (Figure
11A). We conclude that lower expression of TYMSSS due to mRNA based suppression
contributed to the lack of TYMSSS survival advantage. When mRNA regulatory mechanisms are
ablated by codon optimization, TYMSSS has a significant
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Figure 10
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Figure 10 Testing enhanced survival by selection of anti-thymidylate (AThy) resistance
(AThyR) transgenes in Jurkats. (A) The synthesis of thymidine is crucial to DNA replication
and cell survival. It has long been a target of AThy chemotherapeutic agents like methotrexate
(MTX), Pemetrexed (Pem), and 5-fluorouracil (5-FU) in many common forms of cancer. (B)
Putative AThyR transgenes resistant to AThy toxicity were designed in order to confer
resistance to T cells that might be used in a combination therapeutic with AThy chemotherapy.
AThyRs were co-expressed with a fluorescent protein to indicate that surviving cells contained
the transgene. These transgene utilized the Sleeping Beauty transposon/ transposase system
to induce stable transgene expression in Jurkat. Human muteins DHFRFS - resistant to MTX
(left), human mutein TYMSSS - resistant to 5-FU (center), and the gold-standard Neomycin
resistance gene (NeoR) drug resistance gene - resistance to G418 (right) were used in this
study. Codon optimized (CoOp) versions of DHFRFS & TYMSSS replaced native codon DHFRFS
& TYMSSS to test whether known post-transcriptional regulatory mechanisms were affecting
AThyR selection or survival. (C- left) DHFRFS-2A-GFP (DG), CoOp DG, and no DNA, were
electroporated into Jurkat and subjected to MTX after 2 days. (C- center) TYMSSS-2A-GFP
(TSG), CoOp TSG, and No DNA electroporated Jurkat were treated on day 2 with 5-FU. (Cright) NeoR-GFP and No DNA electroporated Jurkat were treated on day 2 with G418. For
each experiment in C the percentage of eGFP+ viable Jurkat is given after testing on day 8-10
after the addition of drug. (D) MTX and Pem are known to inhibit native DHFR and TYMS, DG
and TYMSSS-2A-RFP (TSR) were co-electroporated into Jurkat to determine whether
combination DHFRFS & TYMSSS confer enhanced survival to MTX (left) or Pem (right). (E)
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Following 2 weeks of selection in 1 µM MTX, [DHFRFS & TYMSSS]+ Jurkat displayed a uniform
and repeatable pattern of correlated expression. Shown here, four separate [DHFRFS &
TYMSSS]+ Jurkat experiments are overlaid in different colors. Experiments were independently
repeated at least twice with 4-6 replicates. * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p
<0.0001.

; Dihydrofolate (DHF); DHF reductase (DHFR); deoxyuridine monophosphate

(dUMP); deoxythymidine monophosphate (dTMP); 5, 10 – methylenetetrahydrofolate (5,10
CH2THF); nicotinamide adenine dinucleotide phosphate (NADP).
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Figure 11
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Figure 11 Contributory findings in the testing of individual and combined AThyR
selection for Jurkats. Jurkat were electroporated with AThyR or NeoR drug resistance
transgenes and treated from day 2 until days 10-12 with appropriate drug. The enhancement in
survival of Jurkat expressing transgene is noted in Figure 1. Here the enhanced survival, as
determined by PI exclusion (I), and alterations in the mean fluorescent intensity (MFI) of eGFP
(II), are given for DHFRFS (left), TYMSSS (right), and NeoR (center). (B) Raltitrexed (Ral) is an
anti-folate AThy known to primarily inhibit native TYMS. DHFRFS & TYMSSS were coelectroporated into Jurkat treated with Ral to determine whether this transgene combination
enhanced survival. (C) Observations suggested that cells expressing DHFRFS & TYMSSS as
independent plasmids have correlated expression of each plasmid. This could have
implications in the co-regulation of DHFRFS with TYMSSS. Hence, the MFI of eGFP and RFP
were correlated for treatments with multiple concentrations of MTX, Pem, and Ral. The linear
regression data is included in the figure. Each experiment was independently repeated at least
twice with 4-6 replicates. * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001.

71

expression advantage over mock electroporated Jurkat, and a weak survival advantage in 5 µM
5-FU. The lack of significantly enhanced survival is likely due to an alternative mechanism of 5FU contributing to toxicity, which is likely the known inhibition of mRNA and rRNA synthesis by
5-FU.[85, 99]
NeoR is one of the first drug resistance transgenes utilized in mammalian cells.[45] Here,
NeoR was used to select for enhanced survival of Jurkat in the presence of G418. This was
intended to serve as a standard to gauge the utility of DHFRFS and TYMSSS. Electroporation of
NeoR into Jurkat improved survival in the presence of G418, as expected, at 0.72-1.1 mM
G418 (Figure 10C). The survival advantage of NeoR over No DNA was not significant due to
variability (Figure 11A), but a G418 dependent increase in GFP MFI was noted. The GFP MFI
significantly increased above No DNA Jurkat at 1.4 mM G418 (Figure 11A-II). These results
reinforce that DHFRFS and NeoR are capable of providing dose-dependent transgene selection
advantage in surviving Jurkat. However, only DHFRFS conferred reliable survival advantages to
Jurkat in this experiment (Figure 11A-II).
The next experiment combined DHFRFS and TYMSSS by co-electroporating each
plasmid into Jurkat. The capacity of the combined transgenes to resist commonly used antifolate AThys: MTX, Pem, and Raltitrexed (Ral), were tested. As before, drug was added on day
2 and cells were tested on day 10-12. There was clear selection for [DHFRFS & TYMSSS]
expressing Jurkat in 0.1 - 1 µM MTX when compared to similarly treated No DNA or untreated
[DHFRFS & TYMSSS]+ Jurkat (Figure 10D). It should be noted that endogenous codon DHFRFS
was used in these experiments and the resistance to MTX was enhanced from 0.5 (Figure
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10C) to 1 µM MTX (Figure 10D) by the addition of TYMSSS with no other changes to the
experimental conditions. Selection was also noted for 50-100 µM Pem (Figure 10D). Moderate
selection was also noted with 10 µM Ral when compared to untreated [DHFRFS & TYMSSS]+
Jurkat (Figure 11B). Ral primarily targets TYMS, whereas MTX and Pem target both DHFR
and TYMS,

[86]

hence the improved selection for MTX and Pem over Ral in [DHFRFS &

TYMSSS]+ Jurkat. After 2 weeks within 1 µM MTX, surviving [DHFRFS & TYMSSS]+ Jurkat were
refreshed in untreated media and grown for 3-5 weeks. Subsequently, the stability of transgene
expression of [DHFRFS & TYMSSS]+ Jurkat was tested by flow cytometry with the co-expression
of eGFP representing DHFRFS expression and RFP representing TYMSSS expression as seen
in Figure 10E. Each color represents a separate experiment and is overlaid to represent the
trend that DHFRFS and TYMSSS co-express in a correlated fashion. In fact, analysis of GFP MFI
representing DHFRFS expression and RFP MFIs representing TYMSSS expression over multiple
anti-folate drugs, at multiple concentrations demonstrated that DHFRFS & TYMSSS co-express
with a strong Pearson’s correlation (R2 = 0.9) (Figure 11C). This finding suggests that
expression of DHFRFS is somehow regulated by the expression of TYMSSS, or vice versa.
These findings begin to suggest a more complex mechanism for the expression of DHFR and
TYMS that is inter-related.

Selective propagation of primary human T cells resistant to MTX and/ or 5-FU.
As demonstrated, TYMSSS enhances the ability of Jurkat expressing DHFRFS to survive
in the presence of MTX and Pem, which both target endogenous DHFR and TYMS to prevent
thymidine synthesis. Given the more robust survival to toxic MTX concentrations conferred by
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DHFRFS and TYMSSS, we pursued experiments with MTX as a proof-of-concept to demonstrate
anti-folate and AThy resistance. Based on the findings above, it is anticipated improved survival
in the presence of MTX will translate into improved survival in the presence of Pem. TYMSSS
with DHFRFS were tested in human cells by electroporation into human PBMC.

The day

following electroporation, cells were stimulated with an OKT3-loaded AaPC capable of
polyclonal T cell propagation.[94] The propagation schematic is shown in Figure 12A. Two days
after AaPC stimulation, the co-cultures received 0.1 µM MTX, 5 µM 5-FU, or 1.4 mM G418 until
day 14, as designated in Figure 12. The co-cultures were re-stimulated with AaPC at a 1: 1
ratio and given 50 IU / mL IL-2 every 7 days from day 1 to 35. Phenotypic changes in
transgene expression were tracked during drug administration for the first 14 days and for the
21 days after drug administration had ended. The weekly changes in transgene expression can
be noted in Figure 12B-I, C-I, D-I.
Initial testing of DHFRFS, TYMSSS, and NeoR co-expressed with fluorescent proteins
demonstrated rapid and persistent selection to nearly complete selection for expression of
DHFRFS with MTX and NeoR with G418 (Figure 12B-I). Survival and propagation of AThyR+ T
cells (TAThyR) compared to No DNA T cells on day 21 showed that the presence of AThyR or
NeoR transgene was crucial to T cell survival and growth (Figure 13A). On day 35, total
inferred cell count for T cells expressing AThyR and NeoR transgenes were compared to
untreated No DNA T cells, and NeoR+ T cells were the only T cells with significantly inferior
growth at Day35 (Figure 13B-I). In opposition to experiments in Jurkat, TYMSSS demonstrated
selection within the population of surviving T cells on Day 21 in the presence of
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Figure 12 Selective propagation of primary human T cells resistant to MTX and 5-FU. (A)
Testing for selection of AThyR transgenes in primary T cells was accomplished by coelectroporation of AThyR transposon and SB transposase DNA plasmids into PBMC. The
following day electroporated PBMC were stimulated with OKT3-loaded activating and
propagating cells (AaPC) at a 1:1 ratio and 50 IU/ mL IL-2. Drug was added on day 2 and
maintained at the same concentration until day 14. Every 7 days, fresh AaPC and IL-2 were
added at the same concentration until day 35. (B-I) After electroporation, T cells were tracked
for expression of AThyRs DHFRFS - DG, TYMSSS - TG, both [DG & TSR], and NeoR -NRG in
the presence (day 2-14) then absence (day 14-35) of appropriate selection drug. (C-I) MycffLuc-2A-NeoR (NRF) was combined with each AThyR transgene; [DG & NRF], [TSG & NRF],
and [DG & TSR & NRF] in order to improve selection for AThyRs selected by 5-FU. Selection
occurred under the same condition with the exception that 100 IU IL-2/ mL was added to
promote outgrowth of cells treated with G418. (D-I) To elucidate the influence of 5-FU and
TYMSSS on the selection of DHFRFS, RFP or TYMSSS-RFP (TSR) were co-electroporated into T
cells with DHFRFS. There were no experimental differences from the outline noted in (A). The
percentage of T cells expressing co-receptor CD4 is shown to the right of each corresponding
experiment on Day 35 for B-II, C-II, and D-II. All experiments contain 5-6 biological replicates
with each experiment independently repeated two times. * = p < 0.05; ** = p <0.01; *** = p
<0.001; **** = p <0.0001.
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5-FU. However, the selected TYMSSS expressing T cells did not persist to Day 35, and the lack
of persistence was also noted when [DHFRFS & TYMSSS] were selected using MTX and 5-FU.
One possible explanation for this is that thymidine synthesis is restored by TYMSSS and
thymidine transporters then make thymine available to un-transformed cells. This is likely
mediated by an equilibrative nucleoside transporter as the same transporter that permits 5-FU
entry also mediates equilibrative transport of thymine.[100] As TYMSSS restores thymidine
synthesis in the presence of methotrexate, DHFRFS is no longer able to select for T cells
expressing DHFRFS & TYMSSS as noted in Figure 12B – I.
In order to achieve complete selection of TYMSSS for possible use in combination
therapies, NeoR was co-electroporated into primary T cells with DHFRFS, TYMSSS, and
[DHFRFS & TYMSSS]. The only change made to the propagation method was the addition of
100 IU/ mL IL-2 rather than 50 IU/ mL from days 14-35 to supplement the poor outgrowth
already noted in G418 selected T cells. The higher doses of IL-2 were insufficient to rescue
poor outgrowth when G418 and 5-FU were combined for T cell selection (Figure 13B-II). With
the co-transfection of NeoR into DHFRFS and/or TYMSSS expressing T cells, nearly 100%
transgenes selection was observed with the same transgene selection kinetics among all
groups (Figure 12C-I).
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Figure 13

Figure 13 Propagation characteristics of AThyR+ T cells in the presence or absence of
MTX, 5-FU, and/ or G418. (A) AThyR and NeoR electroporated primary T cells are compared
on Day 21 to mock-electroporated T cells treated with the same conditions. The continued
propagation of the same experiment is shown on day 35 (B-I). This can be compared to day 35
changes in outgrowth potential for primary T cells when NeoR is combined with DHFRFS and/or
TYMSSS (B-II). (B-III) Subsequently, the influence of 5-FU on preserving outgrowth potential for
primary T cells on day 35 was tested. Each experiment was independently repeated at least
twice with 5-6 replicates. * = p < 0.05, ** = p <0.01.
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Figure 14
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Figure 14 MTX alters expression of cis-transgenes co-expressed with AThyRs (A) Jurkat
transformed with DHFRFS - DG, CoOp DHFRFS - CoOp DG, and [DG & TYMSSS - TSR] were
cultured with 1 µM MTX for 2 weeks before culturing without MTX for 3-5 weeks. The stable
fluorescent protein expression, in the absence of MTX, is depicted by MFI. (B-I) AThyR+ Jurkat
were treated for 72 hours with 0.5 µM MTX or no treatment. The ∆ MFI difference (∆ = eGFP
MFI MTX treated – eGFP MFI untreated) is depicted. (B-II) A representative histogram
demonstrates the MTX induced change in eGFP MFI for DHFRFS and CoOp DHFRFS in Jurkat.
In primary T cells from the experiment noted by Figure 2C, day 35 T cells were stimulated with
anti-CD3, anti-CD28 antibodies, and 50 IU/ mL IL-2 in the absence of MTX. The fluorescent
protein MFI is shown in (C), and (D-I) depicts the ∆ MFI after 72 hours of treatment with 0.5 µM
MTX in comparison to no treatment.

(D-II) A representative histogram demonstrates the

observed shift in eGFP fluorescence for DHFRFS+ T cells in the presence or absence of MTX.
Kruskall-Wallis test was used to determine significant differences. (E) Further experiments in
primary T cells assessed the influence of TYMSSS on blunting the MTX-induced increase in
eGFP co-expressed with DHFRFS. This was performed 72 hours after treatment on day 35 with
anti-CD3, anti-CD28 antibodies, 50 IU/ mL IL-2, and varying concentrations of MTX. The MTX
induced change in eGFP MFI for DHFRFS is shown in (I), while the influence of MTX on RFP
and RFP co-expressed with TYMSSS (TSR) is shown in (II). Jurkat and primary T cell
experiments included 6 replicates independently repeated twice; * = p < 0.05, ** = p <0.01, ***
= p <0.001, **** = p <0.0001.
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Figure 15 Flow plots of transgene expression for AThyR experiments on day 35. Flow
plots of CD4 and GFP expression depict day 35 of a series of experiments designed to
characterize the selection and maintenance of transgene expression in donor T cells. T cells
grown for 35 days with days 2-14 in the presence of cytotoxic drugs MTX, 5-FU, G418, or a
combination, as noted above the flow plot, are shown; (A) corresponds to the experiment
described for Figure 2B, (B) corresponds to the experiment described for Figure 2C, (C)
corresponds to the experiment described for Figure 2D. (D) The presence of ffLuc-2A-NeoR –
NRF - on day 35 for experiment noted in (B) is demonstrated using D-luciferin to induce T cell
chemiluminescence.

Each experiment was independently repeated at least twice with 6

replicates. Representative flow plots are depicted. * = p < 0.05, ** = p <0.01, *** = p <0.001.
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The influence of TYMSSS on DHFRFS selection in T cells subjected to MTX was tested.
Plasmids expressing DHFRFS were co-electroporated into T cells along with either TYMSSS coexpressing RFP or a vector expressing RFP alone. This experiment followed the same strategy
as described for Figure 12B. Due to technical limitations, the total amount of DHFRFS
expressing plasmid DNA electroporated into the same number of T cells was decreased.
Consequently, fewer T cells initially expressed DHFRFS at the beginning of the experiment and
DHFRFS was incompletely selected by the addition of MTX within a 14 day time period (Figure
12D - I). The progressive loss of DHFRFS after day 14 is reminiscent of TYMSSS expression in
Figure 12B – I. This demonstrates that AThyR transgenes must select for nearly the entire T
cell population to maintain stable expression within the population. With regards to the
influence of TYMSSS on the selection of DHFRFS, it appears that TYMSSS blunts DHFRFS
selection in T cells as selection of [DHFRFS & RFP] expressing T cells was more robust than
selection of [DHFRFS & TYMSSS] expressing T cells. This is attributed to the restoration of
thymidine synthesis in the presence of TYMSSS (Figure 12D - I). The presence of 5-FU
prevents selection of DHFRFS with or without TYMSSS, and this is attributed to the TYMSSS
independent inhibition of mRNA and rRNA synthesis previously mentioned.[85, 99]
It was also noted that transgenic selection tended to increase the population of CD4+ T
cells by day 35 in all T cell experiments, which was not seen with un-modified T cell cultures.
This was noted in any experiment involving one or more transgenes selected in the presence of
cytotoxic drug (Figure 12B – II, 12C – II, 12D – II, respective flow plots seen in Supplemental
Figure 15A, 15B, and 15C). The experiment in Figure 12D - II demonstrates that it is not
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caused by cytotoxic drug, rather, the presence of transgene in combinations with cytotoxic drug
leads to CD4+ T cell predominance by day 35. The selection towards CD4+ T cell
predominance was not noted 7 days after initial drug selection for AThyR+ T cells (Figure
13C), which is consistent with previously published findings using DHFRFS T cells.[82] The
longer period of follow-up than prior experiments demonstrated a previously unknown
phenomenon that CD8+ T cells are unable to persist for long periods of time following cytotoxic
insult, or are selectively outgrown by CD4+ T cells. The mechanism underlying this
phenomenon is not known.
MTX increases cis-transgene expression in DHFRFS+ T cells

MTX mediated changes in transgene expression could be used in animal models and
humans as a tool for in vivo control of transgene expression. To our knowledge, a system
utilizing clinically available drugs to mediate transgene expression either up or down in T cells
has not been described. Hence, we targeted the known drug-inducible regulation of DHFR by
MTX

[98]

for use in T cells. The MTX-inducible expression of transgenes co-expressed with

mutein DHFRFS is unknown, and the point mutations may have ablated the MTX-inducible
expression mechanism. In order to examine whether this phenomenon persists,

DHFRFS,

CoOp DHFRFS, and [DHFRFS & TYMSSS] expressed in Jurkat were selected in 1 µM MTX for 2
weeks and rested for 3-5 weeks before testing MTX mediated regulation of DHFRFS
expression. By this time, expression of eGFP in each cell was uniformly positive, but the
expression level of eGFP, as signified by the MFI, varied based on the choice of AThyR coexpressing eGFP (Figure 14A). DHFRFS, CoOp DHFRFS, and [DHFRFS & TYMSSS] expressing
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Jurkat were subjected to 72 hours incubation in 0.5 µM MTX, a concentration all DHFRFS+ cells
were expected to survive. Cells treated with MTX showed a significant increase in eGFP MFI
for both DHFRFS and CoOp DHFRFS in comparison to the same cells untreated (Figure 14B-I
and histogram Figure 14B-II). The increase in eGFP MFI was equivalent between DHFRFS and
CoOp DHFRFS after 72 hours, suggesting that the up-regulation of eGFP is independent of the
mRNA binding mechanism previously thought to mediate this phenomenon.[92,

101]

An

alternative regulatory mechanism based on the presence of thymidine is suggested here. As
previously shown, TYMSSS restores the synthesis of thymidine in MTX treated Jurkat. In this
experiment, the co-expression of TYMSSS with DHFRFS in Jurkat blunts the MTX induced
increase in eGFP MFI (Figure 12B-I). Thus, DHFRFS maintains MTX-inducible expression of
cis-transgenes which is dependent on MTX mediated inhibition of TYMS.

This phenomenon was next tested in primary T cells. In order to uniformly select each
AThyR in primary T cells, AThyRs were co-electroporated with a NeoR selection plasmid as
described for Figure 12C-II. By day 35, all AThyR+ T cell groups uniformly expressed
transgene, and the fluorescent protein MFI from each T cell group may be noted in Figure 14C.
On day 35, primary T cells were subjected to 72 hours of 0.5 µM MTX following anti-CD3/
CD28 mediated stimulation. The T cells were tested on day 38, and MTX significantly
increased eGFP MFI for DHFRFS+ cells, as expected. However, upon testing TYMSSS in primary
T cells, it was found that MTX mediates a decrease in eGFP MFI for TYMSSS expressing T
cells (Figure 14D-I). The decrease in eGFP expression demonstrated for TYMSSS+ T cells in
the presence of MTX was consistent across donors and ablated by the restoration of
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dihydrofolate reduction to tetrahydrofolate by DHFRFS. Prior reports demonstrated that
dihydrofolate reversed or prevented TYMS binding to TYMS mRNA.[91] Thus, MTX mediated
decreases in dihydrofolate likely re-establishes TYMS binding to TYMSSS mRNA preventing
expression of eGFP. This phenomenon has not been reported to our knowledge and may be of
scientific and clinical value. Furthermore, TYMSSS continued to blunt the MTX-mediated
increase in eGFP MFI co-expressed with DHFRFS, as was previously noted in Jurkat. The
histogram in Figure 14D-II depicts the MTX-mediated changes in cis-expressed eGFP for
DHFRFS and [DHFRFS & TYMSSS] expressing T cells.

T cells from the experiment shown in Figure 12D were also subjected to varying
concentrations of MTX. On day 35, T cells received anti-CD3/ CD28 stimulation and were
subjected to a range of MTX from 0 to 1 µM for 72 hours. On day 35, no T cell group
significantly expressed DHFRFS, as indicated by co-expressed eGFP, above background
(Figure 12D – I). However, DHFRFS+ T cells selected with MTX alone persisted enough to
significantly improve survival when MTX was re-introduced at concentrations up to 0.5 µM MTX
(Figure 16B). Flow plots in Figure 16A demonstrate MTX-dependent increases in transgene
expression and improved survival for transgene expressing T cells for one donor. It should be
noted that the addition of TYMSSS in [DHFRFS+ & TYMSSS]+ T cells permitted the survival of
transgene negative cells at 1 µM MTX, which was not seen in TYMSSS neg T cells subjected to
MTX (Figure 16C). Presumably, TYMSSS re-established thymidine synthesis in the presence of
MTX and equilibrative thymidine transport permitted transgene negative T cells to restore DNA
synthesis and survive. MTX-inducible up-
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Figure 16
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Figure 16 AThyR rescue of AThyR+ and AThyRneg T cells following 72 hours treatment in
MTX. T cells from the experiment described for Figure 12D were stimulated on day 35 with
anti-CD3, anti-CD28, and IL-2 along with varying doses of MTX [0, 0.1, 0.5, 1 µM] for 72 hours.
The gating strategy and representative flow plots are shown in (A). While enhanced viability of
AThyR+ T cell cultures is shown in (B). In (C), Viable, CD3+, GFPneg, RFPneg T cells (AThyRneg)
were assessed for survival. Each experiment was independently repeated at least twice with 6
biologic replicates total. Representative flow plots from one are depicted; ns = no significance; *
= p < 0.05, ** = p <0.01, *** = p <0.001; **** = p<0.0001.
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regulation of eGFP co-expressed by DHFRFS and blunting of this eGFP up-regulation by
TYMSSS was again observed (Figure 14E – I). Of note, the RFP co-electroporated with
DHFRFS up-regulated in increasing concentrations of MTX, whereas RFP co-expressed by
TYMSSS did not (Figure 14E – II). This further indicates that it is the absence of thymidine
which leads to increases in co-expressed transgene.

AThyR permits independent selection for transgenes of interest.

AThyRs are human proteins and therefore have lower immunogenicity in humans than
NeoR or similar drug resistance transgenes, typically originating from bacteria.[45] Thus, using
AThyRs to select transgenes of interest is desirable due to lower immunogenicity, and ease of
use in vitro. As a proof-of-principle, the suicide gene inducible caspase 9 (iC9) was selected by
co-expressing iC9 with DHFRFS in a construct designated DFSiC9 (Figure 17A). Current
methods to select iC9 utilize surface-expressed antigen and isolation by magnetic beads.[35]
However, this method of selection is more labor intensive than adding drug and does not add
the functionality of AThy resistance. The DFSiC9 plasmid significantly selected for survival in T
cells after 7 days of AaPC based stimulation including days 2 - 7 days in 0.1 µM MTX (Figure
17B). Next, DFSiC9 was co-electroporated with CAR to express in T cells. The CAR was
specifically selected by a CAR exodomain binding ligand (CARL)+ K562 AaPC,[95] while DFSiC9
was selected using 0.1 µM MTX. After days 2 - 14 in 0.1 µM MTX, CAR+ DFSiC9+ T cells were
rested from MTX or selected for another 7 days in 0.1 µM MTX. T cells selected in 0.1 µM MTX
from day 2 - 21 are shown in Figure 17C compared to mock-electroporated T cells. As before,
there is no selection towards CD4+ T cell predominance following MTX selection by day 21.
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Figure 17
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Figure 17 AThyRs select for transgenes of interest. The superior selection of DHFRFS is
desirable for difficult to isolate genes of interest such as suicide genes. Suicide gene inducible
caspase 9 (iC9) was designed to express with DHFRFS in the plasmid DFSiC9 shown in (A). (B)
This construct was tested in PBMC of 3 healthy donors stimulated with a 1: 1 ratio of OKT3loaded AaPC and treated with MTX from day 2 until day 7 when survival is shown. (C) T cells
were electroporated with CD19-specific chimeric antigen receptor (CAR), DFSiC9, and SB
transposase and expanded on CARL+ K562 in the presence of MTX for 21 days to select for
each transgene. The expression of costimulatory T cell receptors CD4, CD8, and transgenes
CAR and DHFRFS are shown in 21 day CARL expanded transgenic T cells in comparison to
mock electroporated T cells expanded on OKT3-loaded AaPC clone.4. (D) The effect of MTX
on cytotoxicity in DHFRFS+ CAR+ T cells was tested by stimulating CAR+ T cells in the presence
or absence of MTX for 7 days after stimulation on day 14. Cytotoxicity was assessed by CRA
on Day 21 using CD19 positive or CD19 negative murine lymphoma EL-4 cells. T cells were
co-incubated with EL-4 at a 1 target: 5 effector ratio. (E) The functionality of iC9 was assessed
on day 21 by resting T cells for 48 hours in 10 nM AP20187. T cells had previously been
stimulated for 7 days in the presence or absence of MTX. Comparison of surviving CAR+ T
cells is made to matched, un-treated cells. Experiments in C-E were performed with 4 normal
donors and repeated twice. Significance for each comparison was initially determined by TwoWay ANOVA followed by Sidak’s post-hoc analysis; * = p < 0.05, ** = p <0.01, *** = p <0.001,
**** = p <0.0001.
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These cells also demonstrated cytotoxicity at the levels expected for the given 5 : 1 target to
effector ratio (Figure 17D).[95] These findings agree with that of Jonnalagadda et al. who linked
DHFRFS to CAR expression and noted cytotoxicity independent of MTX treatment.[82] Coexpressing DHFRFS with iC9 rather than CAR added the potential to ablate T cells through the
addition of iC9 chemical inducer of dimerization AP20187 (Figure 17E). The addition of
AP20187 significantly depleted resting CAR+ T cells independent of MTX. This demonstrates
that DFSiC9 can effectively select for iC9 expression and deplete genetically-modified T cells as
necessary. The use of DHFRFS has the advantage of selecting transgene expression in T cells
independent of antigen-specificity and antigen expression, making DHFRFS a more portable
tool for use in a variety of T cell studies.

DISCUSSION:

Our work establishes 3 findings relevant to investigators designing genetically-modified
T cell studies; 1) AThyRs rescue T cells from AThy toxicity mediated by 5-FU and anti-folates
targeting DHFR and TYMS. 2) DHFRFS permits MTX-inducible increase in transgene
expression that is thymidine dependent, and TYMSSS permits MTX-inducible decrease in
transgene expression that is dihydrofolate dependent. 3) AThyRs can be used to positively
select for transgenes of interest without the use of immunogenic genes or magnetic selection.
To the first point, we demonstrate that combining AThyRs DHFRFS and TYMSSS leads
to significant survival advantages for T cells treated with toxic concentrations of AThys: MTX,
Pem, or 5-FU. These AThy drugs are regularly used to treat lung and colon cancer among
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other common cancers,

[85, 86]

and our findings indicate that AThyRs can survive toxic AThy

concentrations. It has been shown that myeloid derived suppressor cells, which suppress T cell
targeting of cancer cells, are selectively depleted by 5-FU.[102] Likewise, in a mouse model
combining 5-FU with an immunotherapeutic strategy, it was shown that 5-FU increases Fas
expression on cancer cells and leads to improved targeting of cancer cells when the two
therapies were combined, but not when either strategy was used alone.[103] Thus, combining
the immunomodulatory effects of chemotherapy like 5-FU with T cells resistant to the cytotoxic
effects of 5-FU could substantially improve the anti-cancer response of the patient above that
of either therapeutic used alone. This supports further in vivo study of an autologous tumor
and T cell system where the tumor is concurrently treated with AThys and AThyR+ T cells. An
in vivo model should resolve the issue of whether CD4+ T cell predominance in AThyR+ T cells
persists and if it leads to any detrimental consequences of tumor clearance. As for the use of
AThyRs to prevent anti-folate toxicity from MTX or Pem, we establish that MTX is more toxic to
T cells than Pem and find that MTX susceptibility to < 1 µM MTX could be completely
abrogated by the codon optimization of DHFRFS or by the addition of TYMSSS to DHFRFS in T
cells. Concentrations of up to 1 µM MTX are achieved during the treatment of rheumatoid
arthritis.[104] Higher doses of MTX are achieved in cancer chemotherapy (> 1mM MTX) with the
use of leucovorin.[105] Leucovorin rescues thymidine synthesis through the same pathway as
combination DHFRFS and TYMSSS. Thus, [DHFRFS & TYMSSS]+ T cells will likely resist
cytotoxicity induced by the range of MTX experienced for both immune suppression and cancer
treatment, but this remains to be tested in in vivo models.
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Figure 18

Figure 18 Post-transcriptional regulation of thymidine synthesis locks expression of
DHFR to TYMS. MTX-induced increases in DHFR expression were inhibited by restoration of
thymidine synthesis (TMP – thymidine monophosphate from UMP - uridine monophosphate).
Likewise, MTX-induced decreases in TYMS expression were restored to normal levels by the
restoration of DHFR activity reducing DHF – dihydrofolate to THF - tetrahydrofolate. These
findings

link

expression

of

transgenic

DHFR

methylenetetrahydrofolate (5,10 CH2THF)
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With regard to the second finding, we establish that MTX can be used to regulate
transgene expression either to higher or lower expression levels for a transgene expressed cis
to DHFRFS or TYMSSS, but not [DHFRFS & TYMSSS]. We note that the increased expression of
eGFP expressed cis to DHFRFS was blunted by the restoration of thymidine synthesis by
TYMSSS. Likewise, we found that the decreased expression of eGFP expressed cis to TYMSSS
was lost when DHFRFS permitted the reduction of dihydrofolate. Figure 18 depicts this
relationship of the metabolite of one enzyme to the expression of the other. From this
interrelationship it becomes clear that DHFR and TYMS expression is linked. Thus, there is
evidence that the correlated expression of DHFRFS and TYMSSS, noted in Figure 11C, is
biologically linked. The influence of TYMS activity on DHFR expression[92] and the influence of
DHFR activity on TYMS expression[96] are known, but the functional linkage in expression
between DHFR and TYMS has not been examined to our knowledge. Clinical utility of the
MTX-inducible increase or decrease of transgenes co-expressed cis to AThyR transgene is
unknown. However, earlier studies in mice utilized transgenic tumor cells containing native
DHFR linked to HSV-TK1 and found a 1.5- 4 fold increase of HSV-TK1 functionality with the
addition of MTX.[98] Therefore, MTX-inducible positive or negative modulation of cis-transgenes
could lead to clinically useful methods where MTX is used to modulate the spatial and temporal
expression of dangerous but necessary transgenes, such as certain CAR or cytokine.[25] The
correlated expression of DHFRFS with trans expressed TYMSSS may also have clinical utility in
expressing proteins such as TCR α and β that need to be expressed at nearly equivalent
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amounts and where the use of 2A mediated cleavage sites may adversely affect protein
structure and function.[106]

For the purpose of selecting genes of interest, AThyRs were compared to one of the
earliest drug resistance transgenes – NeoR.[107] This was also the first drug resistance
transgene used in humans.[43] It was found that DHFRFS is superior to NeoR in promoting
survival, selection, and drug-dependent increases of expression for eGFP. Notably, DHFRFS
and TYMSSS have lower immunogenicity as human proteins, and MTX can be used both in vitro
and in vivo

[46]

to improve transgene selection whereas G418 cannot.[108-110] Our findings that

DHFRFS can select for cells expressing important transgenes such as the suicide gene iC9
makes DHFRFS and [DHFRFS & TYMSSS] a reasonable alternative to magnetic beads for
selecting a gene or genes of interest. In fact, the potential to select for AThyR+ T cells in vivo
using MTX suggests that transgene selection could be performed within the patient rather than
ex vivo.
In conclusion, the use of AThyR transgenes DHFRFS and TYMSSS alone or in
combination provides a unique capacity to select for transgene expression within the bulk
population, modulate the expression of cis as well as trans transgenes, and promote survival in
toxic concentrations of AThys. Our findings broaden the potential use of DHFRFS in
combination with TYMSSS to cancers such as lung, colon, breast, and pancreas that are in dire
need of new therapeutic options. In a future application we seek to combine AThyRs with
pancreatic cancer specific T cells to enhance anti-tumor efficacy.
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CHAPTER 4: Development of pharmacological approaches to select
or deplete Tregs
INTRODUCTION:

Regulatory T cells (Treg) are a subset of T cells vital to the balance of the adaptive
immune response. If Treg are deficient or defective, then autoimmunity develops.[111] If Treg are
dominant within an environment, then immune-tolerance permits the outgrowth of tumors.[112]
Thus, control of Treg is desirable for the treatment of a large number of human diseases falling
under the category of autoimmunity or cancer. However, the rarity of this T cell subset[11] and
the challenging nature of selecting for these cells, which are characterized by the expression of
an intracellular transcription factor –FoxP3- in addition to other markers,[111, 113] makes studying
how these cells are selectively expanded or depleted a difficult task.

Selection of Treg is desirable for the treatment of autoimmunity and occurs with several
therapeutics by differing mechanisms of action such as irradiation,[114] MTX, 5- fluorouracil (5FU),[115] 5-azacytidine,[116] and cilostamide.[117] These findings were described in vitro and in
vivo using rodent models.[116-120] In humans, an increase in Treg was noted following the
administration of multi-drug regimens to treat cancer.[121] A shared mechanism of action for
preferential selection of Treg is not clear, but MTX appears to be a strong candidate for
understanding how Treg selection is occurring. MTX has a known role in inhibiting purine
metabolism

[86]

similar to cilostamide, thymidine synthesis similar to 5-FU,

[86]

and DNA

methylation[122] similar to 5-azacytidine, each of which selects for Treg as noted. MTX inhibits de
novo purine synthesis upstream at Glycinamide ribonucleotide transformylase (GART),
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downstream at 5-aminoimidazole-4-carboxamide riboside (AICAR) transformylase (AICARtf),
de novo thymidine synthesis at thymidylate synthase (TYMS), and single carbon metabolism,
which includes methylation, at dihydrofolate reductase (DHFR) (See Figure 19A).[86] Since
MTX is first-line therapy in the treatment of severe rheumatoid arthritis[123] and GvHD
prophylaxis,[124] discerning how MTX influences Treg selection is of clear importance.

Depletion or blocking of Treg is currently most effective using biological agents in the
treatment of cancer.[112] This is exemplified by anti-CTLA-4 therapy,

[125]

which depends in part

upon the inhibition of Treg.[126] Among non-biological agents, cyclophosphamide is thought to
deplete Treg [112, 127, 128] in the treatment of cancer.[129, 130] However, this finding may be dose and
time dependent[128][131] The mechanism of cyclophosphamide induced Treg depletion may be
related to adenosine monophosphate (AMP) Kinase (AMPK) as cyclophosphamide is known to
deplete levels of ATP within Treg,[127] and low levels of ATP are known to activate AMPK.[132]
Recent findings of Treg depleting gene targets 3-hydroxy-3-methyl-glutaryl (HMG)-CoA
reductase

[133]

and p300

[134]

are also AMPK targets – further implicating AMPK in a pathway of

Treg survival. In this study, we demonstrate AMPK signaling is enhanced in activated Treg, and
we further demonstrate that AMPK target ribosomal translation via eukaryotic elongation factor
– 2 (eEF2).[135][136] Interestingly, MTX potentiates activation of AMPK via the inhibition of
AICARtf.[137] This suggests that an AMPK – eEF2 axis may be involved in the selection or
depletion of Treg.
To determine the influence of MTX on Treg selection, we utilize DHFRFS and TYMSSS
capable of resisting MTX and 5-FU targeting of native DHFR or TYMS, respectively. We find
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that alleviating thymidine blockade of MTX promotes Treg expansion, likely through inhibition of
purine synthesis. Further analysis of TCD4,

FoxP3

selection by MTX and toxic agents targeting

similar pathways suggests that inhibited purine synthesis is not the primary mechanism of Treg
selection. Rather, inhibition of Treg replication by inhibited ribosomal protein translation appears
to mediate selection in chemotherapy. Multiple drugs are known to inhibit ribosomal synthesis
and translation,[99, 136] and rapamycin, a drug commonly used in Treg selection,[138] also inhibits
translational initiation and ribosomal synthesis.[139] Our study elucidates a common pathway for
the selection and depletion of Treg, and consequently develops a novel method to transgenically
improve selection of Treg as well as a biochemical method to deplete Treg.

MATERIALS AND METHODS:
Cells and culture conditions:

Cells: Healthy donor derived peripheral blood from MDACC Blood Bank, Houston, Texas, was
subjected to density gradient centrifugation to isolate mononuclear cells which were either
rested in complete media (CM) or frozen as previously outlined. The use of rested or frozen
peripheral blood derived mononuclear cells (PBMC) is outlined in each experiment. T cells from
PBMC were stimulated using thawed OKT3 antibody-loaded K562 clone #4, an activating and
propagating cell (AaPC).[94]

The presence of mycoplasma was tested in AaPC before

stimulation of T cells. Cell counting was accomplished by 0.1 % Trypan Blue (Sigma-Aldrich,
T8154) exclusion using automated cell counting (Nexcelcom, Lawrence, MA). Cell Isolation
was accomplished using magnetic bead based sorting with the CD4+, CD25+ Regulatory T Cell
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Isolation Kit following the manufacturer’s instructions (Miltenyi Biotec, San Diego, CA, 130-091301). Briefly, CD4+ T cells were negatively selected before sorting one time with anti-CD25
beads was used to differentiate between effector T cells (CD25neg) and Treg (CD25pos).

Culture Conditions: Acellular stimulation was accomplished as previously described using
soluble anti-CD3 – 30 ng/ mL, anti-CD28 – 100 ng/ mL, and human IL-2 – 50 IU/ mL, as
previously described . When indicated, the following drugs were used: 5-FU, MTX, cisplatin
(CDDP), pemetrexed, raltitrexed, G418, hygromycin B, zeocin, rapamycin, metformin, AICARtf
/ inosine monophosphate (IMP) cyclohydrolase (ATIC) dimerization inhibitor (iATIC) (Table 8).
Acellular stimulation experiments received addition of toxic drug or treatment on the same day
as stimulation.

DNA expression plasmids:
Selection vectors: FLAG-DHFRFS-2A-eGFP pSBSO (noted as DHFRFS-GFP (DG)),
FLAG-TYMSSS-2A-eGFP pSBSO (noted as TYMSSS-GFP (TSG)), NLS-mCherry pSBSO
(RFP), FLAG-TYMSSS-2A-NLS-mCherry pSBSO (noted as TYMSSS-RFP (TRG)), Neomycin
Resistance (NeoR)-2A-eGFP pSBSO (noted as NeoR-GFP (NRG)), and Myc-ffLuc-NeoR
pSBSO (NRF), were designed constructed and utilized as previously described . Sleeping
Beauty (SB) indirect/ direct repeat (IR/DR) sites were present in each construct to induce
genomic integration with SB transposase. Each transgene was expressed by elongation factor
1 alpha (EF1α) promoter.
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Table 8 Chemical Agents

Agent

Manufacturer

ID No.

5-fluorouracil

APP Pharmaceuticals, Schaumburg, IL

NDC 63323-117-10

Methotrexate

Hospira, Lake Forest, IL

NDC 61703-350-38

CDDP

Pfizer, New York, NY

NDC 0069-0084-07

Pemetrexed

Lilly, Indianapolis, IN

NDC 0002-7640-01

Raltitrexed

Abcam Biochemicals, Cambridge, MA

Ab142974

iATIC

EMD Millipore

118490

G418

Invivogen, San Diego, CA

Ant-gn-1

Hygromycin

Invivogen

Ant-hg-1

Zeocin

Invivogen

Anti-zn-1

Rapamycin

Wyeth, Philadelphia, PA

NDC 0008-1030-04
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Genetic Transformation and Propagation of Cells:
The Amaxa Nucleofector® II was utilized to transform human PBMC, where 1-2*107
thawed PBMC were electroporated in Amaxa T cell Nucleofector solution using program U14,
as previously described . The next day, PBMC were stimulated with CM with AaPC at a ratio of
1: 1 including 50 IU/ mL IL-2. The co-culture of T cells and AaPC was maintained at 1*106 cells/
mL with each subsequent stimulation. Outgrowth of T cells was promoted by re-stimulated of
co-cultures every 7 days with IL-2 and AaPC at the concentrations noted. Fresh IL-2 was
added when media was changed between stimulations. During transgenic experiments, drugs
were added 48 hours after co-culture initiation and maintained at the given concentration until
day 14. After day 14, no drugs were added to T cell cultures.

Western blot:

When noted, T cells were removed from cultures for western blot by centrifugation of
1*106 T cells, and rapid freezing of the cell pellet in liquid nitrogen. T cell pellets were lysed and
prepared with 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 1mM
phenylmethylsulfonyl fluoride, 150 mM p-nitrophenyl phosphate and 0.3 µM Aprotinin, pH
7.4. SDS-PAGE separated proteins and primary antibodies noted in Table 9 were used to
detect the presence of protein via chemiluminescence.
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Table 9 Western Blot Antibodies

Antibody

Manufacturer

Cat. No.

Dilution

AMPKα

Cell Signaling Technology (CST), Danvers, MA

2603S

1: 1000

(T172)

CST

2535S

1: 1000

S6

CST

2317S

1: 1000

(S235/236)

CST

3945S

1:1500

Actin

Sigma

A2228

1:10000

Hsp-70

Santa Cruz Biotechnology, Dallas, TX

SC-24

1:5000

eEF2

LifeSpan Biosciences, Seattle, WA

LS-B8940

p-eEF2 (T56)

LifeSpan Biosciences

LS-C198899

p-AMPKα

p-S6
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Flow cytometry:
Cultured T cells were washed in FACS staining solution[95] before surface antibody
staining was performed in FACS staining solution with fluorochrome-conjugated antibodies at
4º C for at least 30 minutes. Intracellular transcription factor and cytokine staining utilized the
FoxP3 / transcription factor staining buffer set manufacturer’s protocol (eBioscience, 00-552300), and was performed following surface staining. The BD FACSCalibur (BD Biosciences)
analyzed

most

samples

expressing

FoxP3.

Antibody

targets,

concentrations,

and

manufacturers are listed in Table 10. Flow cytometry data analysis utilized FlowJo v 10.0.5
(Tree Star Inc., Ashland, OR). Flow cytometric imaging of cells stained for phosphorylated
antigens was accomplished using the ImageStreamX Mark II (Amnis, Seattle, WA) with the
following protocol; after surface staining, samples were fixed in 100% methanol (Sigma) for 1
hour at 4º C before washing and staining in FoxP3 / transcription factor staining buffer set wash
buffer as outlined by the manufacturer’s protocol. Analysis of image cytometry data utilized
Amnis IDEAS v 6.0.

Thymidine Incorporation Assay:

A thymidine incorporation assay was performed with anti-CD3/ CD28 and IL-2 used to
stimulate each well containing 2 * 105 viable cells. Varying ratios of effector T cells (Teff) to Treg
were combined in each well and all wells were run in triplicate in U-bottom 96 well plates. At 48
hours 1 µCi [3H] Thymidine (Perkin-Elmer, Waltham, MA) was added to each well, and 24
hours later the cells were assessed for radioactivity on a Top Count NXT (Perkin-Elmer). Treg

104

mediated suppression of growth was determined by the following equation: (No Treatment Teff
[cpm] - (Treg & No Treatment Teff [cpm])) / No Treatment Teff [cpm].

Statistical Analysis:

Graphical representation and statistical analysis of data was performed with Prism v6.0
(Graph Pad Software Inc., La Jolla, Ca). One-Way ANOVA was used when appropriate with
Tukey’s or Dunnett’s multiple comparison tests as applicable, non-Gaussian distributions were
assessed by the Kruskall-Wallis test followed by Dunn’s multiple comparison test. Total cell
counts and expression data involving TCD4,

FoxP3

tended to be non-Gaussian in distribution.

Single variable tests (experimental vs. control) were made using the Mann-Whitney test.
Statistical significance was designated as α < 0.05.
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Table 10 Flow Cytometry Antibodies

Antibody

Manufacturer

Cat. No.

Dilution

CD3-APC

BD Pharmingen

340661

1:33

CD3-PerCP-Cy5.5

BD Pharmingen

340949

1:33

CD4 FITC

BD Pharmingen

340133

1:33

CD4 -PE

BD Pharmingen

347327

1:33

CD4-PerCP-Cy5.5

BD Pharmingen

341645

1:33

CD8-APC

BD Pharmingen

340659

1:33

CD25-APC

BD Pharmingen

555434

1:33

CD39-APC

BD Pharmingen

560239

1:33

CD45RO-APC

BD Pharmingen

559865

1:33

CD152-APC

BD Pharmingen

555855

1:33

KI-67-AF647

BD Pharmingen

561126

1:50

Annexin V

BD Pharmingen

556422

1:20

7-AAD

BD Pharmingen

559925

1:20

Propidium Iodide

BD Pharmingen

556463

FoxP3-PE

eBiosciences

12-4777-42

1:20

Helios-APC

Biolegend

137222

1:05

LAP-APC

Biolegend

349608

1:20

IFN-g-APC

Biolegend

502516

1:20

106

IL-2-APC

Biolegend

500315

1:20

LifeSpan
p-eEF2 (T56)

Biosciences

LS-C198899

1:20

p-AMPKα (T172)

AbCam

Ab133448

1:20

CD4-Pacific Blue

BD Pharmingen

558116

1:33

BD Pharmingen

560465

1:20

Life Technologies

A-11034

1:100

p-S6

(S244)

–

AF647
Goat anti-Rabbit –
AF488
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RESULTS:
Drug selection of TCD4, FoxP3 by MTX occurs in part through toxicity.

In order to determine how MTX contributes to the selection of TCD4, FoxP3, freshly derived
PBMC were stimulated with anti-CD3/ CD28 antibodies and IL-2 in the presence of cytotoxic
drugs or lethal γ-irradiation. After 7 days there was a significant difference in survival markers
Annexin V and 7-AAD in stimulated T cells receiving any cytotoxic insult with stimulation
(Figure 19B-I). The selection of TCD4,

FoxP3

was not as consistent as cytotoxicity. Following 7

days of stimulation, 2 Grey γ-irradiation significantly increased the amount of TCD4, FoxP3 in the
surviving population (Figure 19B-II). This lethal treatment did not target a common pathway
being considered, nor did cisplatin, yet both increased TCD4,

FoxP3.

However, the TCD4,

FoxP3

increase induced by cisplatin is insignificant. The only significant increases derived from drugs
in this experiment were 5-FU and MTX, recapitulating earlier findings.[115] With the exception of
ribosomal elongation inhibitor G418,[140] each cytotoxic treatment appeared to increase the
percentage of surviving TCD4, FoxP3. This pattern of increasing TCD4, FoxP3 percentage in the face of
varied cytotoxic insult suggests a common pathway that can be enhanced by certain drugs.
This pathway is likely related to the slower proliferation rate of Treg,

[141]

and appears to be

ribosomally mediated as G418 can inhibit this general trend of increasing TCD4, FoxP3 percentage.
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Figure 19

109

Figure 19 Drug selection of TCD4, FoxP3 by MTX occurs in part through toxicity. The known
selection of TCD4, FoxP3 by MTX was analyzed by targeting enzymes that contribute to the action
of MTX. As TCD4,

FoxP3

are a rare component of PBMC, drug based inhibition was originally

sought to analyze the phenomenon. Multiple drugs with actions similar to MTX were used to
assay for the selection of TCD4, FoxP3. In this case, γ-irradiation, G418, and cisplatin (CDDP) were
used for controls as none of those treatments act on the known enzymatic targets of MTX. The
association of each drug to the enzyme targets of MTX is shown in A. PBMC stimulated with
anti-CD3/ CD28 and soluble human IL-2 were given lethal doses of each treatment and
assayed after 7 days for viability B-I. These treatments resulted in variable selection for TCD4,
FoxP3

on day 7 as seen in B-II. The inability of folate analogs targeting DHFR, TYMS, or GARFT

to significantly select for TCD4,

FoxP3

suggested that inhibition of ATIC contributes to this

selection. A dose dependence study followed analyzing the contribution of ATIC inhibitor in the
selection of TCD4,

FoxP3.

The study in B-II noted that G418 depleted TCD4,

FoxP3,

thus, this was

used as a negative control while the known selection of TCD4, FoxP3 by rapamycin (Rapa) was a
positive control. A non-folate analog known to inhibit ATIC (iATIC) was used as a specific
inhibitor of ATIC. The cytotoxicity of G418 C-I, MTX D-I, iATIC E-I, and Rapa F-I is shown in
the top panel while the selection for TCD4, FoxP3 is shown in the bottom panel for G418 C-II, MTX
D-II, iATIC E-II, and Rapa F-II. The drug iATIC did not select for TCD4,

FoxP3,

ruling out this

pathway as the primary means of MTX selection. However, visual inspection of the flow plots
for CD4 and FoxP3 expression in G, represented by one donor, demonstrate that FoxP3
expression was enhanced by iATIC similar to the action of Rapa, suggesting that MTX
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selection relies in part on cytotoxicity and in part by inhibition of ATIC to enhance selection of
TCD4, FoxP3. All assays used 4-7 donors independently repeated 2-3 times. Statistical significance
was assessed using One-Way ANOVA for viability and Kruskall-Wallis test for percentage of
TCD4, FoxP3; * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001.
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The findings of Treg depletion with G418 and Treg selection by MTX were further
evaluated for dose dependence by stimulating thawed PBMC with anti-CD3/CD28 + IL-2 for 7
days, as before. G418 was significantly cytotoxic at all doses tested, but significantly depleted
TCD4,

FoxP3

at two moderate drug doses (Figure 19C). MTX was also cytotoxic at all doses

tested, but had significant elevation of TCD4,

FoxP3

at lower doses (Figure 19D). Rapamycin

(Rapa) was used as a Treg selection control[138] and showed similar TCD4,

FoxP3

selection at a

moderate drug concentration independent of cytotoxicity, which only occurred at the highest
doses (Figure 19F). The selection for or against Treg at moderate drug doses rather than higher
doses suggests that Treg have a narrow therapeutic window for drug induced selection or
depletion. A specific inhibitor of ATIC

[142]

was used to test whether MTX mediates selection of

TCD4, FoxP3 through inhibition of ATIC. Inhibition of AICARtf or the heterodimeric complex ATIC,
in which AICARtf is found, increases AICAR. AICAR is known to activate AMPK,[142] and it is
known that activated AMPK inhibits ribosomal activity through inhibition of mTORC1[136] and
eukaryotic elongation factor 2 (eEF2).[139] Figure 19E demonstrates that ATIC inhibition alone
was neither cytotoxic nor selective for TCD4, FoxP3. Further analysis of flow plots represented by
the same donor in Figure 19G show expression of CD4 and FoxP3 for several of the drugs
used. Use of iATIC characteristically mediated increased expression of FoxP3 in CD4+ T cells
similar to that of Rapa, but did not inhibit proliferation of FoxP3neg T cells as MTX, G418, or
Rapa. Thus, iATIC enhanced FoxP3 expression in CD4+ T cells but diluted these cells by
permitting proliferation of FoxP3neg T cells. It appears that MTX mediated selection of TCD4, FoxP3
occurs by depletion of rapidly proliferating effector T cells and enhancement of FoxP3

112

expression via a pathway similar to Rapa that includes ribosomal inhibition. The increased
susceptibility of Tregs to ribosomal inhibitor G418 solidifies this relationship between enhanced
FoxP3 expression and increased susceptibility to ribosomal inhibition.

Tregs are preferentially expanded in primary T cells resistant to the anti-folate and antithymidine actions of MTX.
Prior studies by Jonnalagadda et al. have demonstrated the potential of DHFRFS to
promote T cell survival in the presence of MTX.[46, 82] We previously performed selection studies
of DHFRFS transgene in bulk human PBMC using MTX and found CD4+ T cells predominance.
The preference of multiple drug selection vectors to selectively propagate CD4+ T cells in the
same way suggested a common phenomenon. It was hypothesized that regulatory T cells were
inhibiting CD8+ T cells proliferation following drug selection.

To test this hypothesis, drug

resistant T cells were derived by transformation with DHFRFS, TYMSSS, NeoR, or a
combination, and numerically expanded as previously described. Briefly, transformed T cells
were selected in the presence of 0.1 µM MTX, 5 µM 5-FU, or 1.6 mM G418 as designated from
day 2 to 14 while stimulation with OKT3-loaded AaPC and 50 IU / mL IL-2 occurred every 7
days until day 35.[94]
Initial testing for Tregs by elevated expression of FoxP3 in the CD4+ T cell population
demonstrated there was a significant TCD4, FoxP3 percentage increase in DHFRFS expressing T
cells. Selection using MTX in comparison to mock-electroporated (No DNA) T cells on Day 21
showed this increase (Figure 20A), and this increase persisted to Day 35 when 5-FU was
combined with MTX during selection (Figure 21A). The transgenic T cells were almost entirely
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CD4+ in each experimental population after selection, but the predominance of Tregs appeared
to often exceed the 5-10% typically found in the un-manipulated CD4+ T cell compartment.[141]
Markers of Treg function were also assessed. Low IL-2 expression

[113]

is a known trait of Tregs

and is assessed with FoxP3 expression. The percentage of the T cell population with a
FoxP3pos, IL-2neg expression pattern is shown in Figure 21B. Expression of latency associated
peptide (LAP) - a part of the TGF-β complex [143] and strongly associated with activated Treg, and
is seen in Figure 21C. The protein CTLA-4[113] mediates intercellular inhibition of effector T cell
responses and is shown by FoxP3+, CTLA4+ expression in Figure 21D. These findings help to
corroborate whether the TCD4, FoxP3 in each experiment were Treg as donor to donor variability
and low TCD4, FoxP3 numbers made suppression assays an ineffective Treg measure.
The transgenes DHFRFS and TYMSSS were compared individually and in combination to
the control selection vector NeoR and un-treated No DNA T cells. Selection towards Treg in this
experiment may be noted in Figure 21A, B, C –I. This experiment demonstrated that [DHFRFSGFP (DG) & TYMSSS-RFP (TSR)]+ T cells selected in MTX + 5-FU had an increased population
of cells characteristic of Treg when compared to mock-transformed T cells. To further elucidate
the contribution of DHFRFS and TYMSSS to Treg selection, NeoR was co-electroporated with
DHFRFS, TYMSSS, or the combination. The addition of NeoR permitted equivalent selection of
DHFRFS, TYMSSS, and the combination in all T cell populations. With un-transformed T cells
removed, it became clear that DHFRFS alone, but not TYMSSS alone could select for cells
characteristic of Tregs (Figure 21A, B, and C –II). [DG & TSR]+ T cells continued to select for
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Figure 20
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Figure 20 Correlative findings in the selection of Tregs from primary T cells through
resistance to the anti-DHFR and anti-TYMS actions of MTX. Selection of TCD4,
assessed at day 21 in each experiment. The selection of TCD4,

FoxP3

FoxP3

was

in the experiment

corresponding to column I of Figure 21 is shown in A. It is notable for the rescue of TCD4, FoxP3
with NeoR and early selection of TCD4, FoxP3 with MTX selection of DHFRFS. Flow plots in B show
co-expression of FoxP3 with IL-2 top row, LAP middle row, or CTLA-4 bottom row for the
same experiment after stimulation on Day 35. This experiment utilized 5 donors and was
independently repeated twice. Significance was assessed by Two-Way ANOVA and Sidak’s
post-hoc; * = p < 0.05, ** = p < 0.01.
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Figure 21
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Figure 21 Primary T cells resistant to the anti-DHFR and anti-TYMS actions of MTX
preferentially expand Tregs. Primary T cells were electroporated with DHFRFS and TYMSSS
transgenes resistant to the anti-DHFR and anti-TYMS actions of MTX, respectively, in order to
assess the contribution of each pathway to the selection of TCD4,

FoxP3.

T cells were

electroporated with plasmids expressing drug resistant transgenes and stimulated with artificial
antigen presenting cells (AaPCs) weekly at a 1: 1 ratio. T cells were selected for 2 weeks in the
combined with TYMSSS-2A-RFP (TSR) and selected using both MTX and 5FU, or control
selection vector NeoR-2A-GFP (NRG) selected with G418. Selection of TYMSSS by 5-FU was
incomplete. Thus, ffLuc-2A-NeoR (NRF) vector was included with the MTX resistant
transgenes DG, TSG, or [DG & TSR] to remove untransformed T cells in the experiments
shown in column II. Equivalent selection for each transgene showed that MTX enhanced
selected for Treg in the presence of MTX resistant DHFR. It was still uncertain whether the
enzymatic activity of TYMS or 5-FU played a part in the selection of Treg. Therefore, the
experiment shown in column III was performed to test the influence of TYMS inhibition in the
selection of Treg.

Selection of Treg phenotype was found to be associated with 5-FU, but

independent of TYMS activity. The Kruskall-Wallis test was used to assess differences
between groups for 5-6 biologic replicates and tests were independently repeated twice; * = p <
0.05, ** = p <0.01.
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cells with Treg features. Finally, the contribution of TYMSSS to the selection of Treg by DHFRFS
was assessed by co-electroporation of TSR or a control vector- RFP. The characteristics of
Tregs from this experiment are shown in Figure 21A, B, and C–III. This experiment
demonstrates that selection of DHFRFS with MTX can enhance outgrowth of Treg and that 5-FU
enhances this selection independent of TYMSSS. Selection of Treg required folate rescue by
DHFRFS. This is expected as folate is known to be crucial to Treg survival.[144] Surprisingly,
selection of Treg did not require de novo thymidine synthesis as TYMSSS, which alleviates MTX
and 5-FU inhibition of TYMS, was dispensable.

Previous findings showed survival and toxicity of 5-FU in PBMC is mediated by TYMS
and an alternative mechanism.[145] RNA inhibition, [85] including inhibition of ribosomal synthesis,
[99]

is a known alternative mechanism. Combining the known mechanisms of Treg selecting

drugs MTX, 5-FU, and rapamycin yielded the diagram in Figure 22, which details how each
drug interacts with ribosomal function. It was noted in an experiment depicted in Figure 20A
that Neomycin resistance gene rescued TCD4,

FoxP3

from the treatment of G418. This finding

suggests that a specific action of G418 is responsible for TCD4,
phenomenon was further explored.
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FoxP3

depletion, and this

Figure 22

Figure 22 Diagrammatic representation of biochemical and protein interactions thought
to influence selection of Treg
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Ribosomal Inhibition by aminoglycoside G418 selectively depletes replicating TCD4, FoxP3.

Thawed PBMC were activated with anti-CD3/CD28 + IL-2 for 7 days in the presence of
alternative doses of G418, Hygromycin B - a different aminoglycoside,[146] Zeocin – a DNA
targeting antibiotic, and Rapa to assess the dose dependent selection or depletion of TCD4, FoxP3
by aminoglycosides (Figure 23A). Depletion of TCD4,

FoxP3

is again noted in the presence of

aminoglycoside G418. The alternative aminoglycoside - hygromycin – developed an
insignificant increase in TCD4, FoxP3 at 0.2 mM hygromycin. This increase significantly decreased
with higher doses of hygromycin - 1.5 and 2.3 mM. Hygromycin showed no significant depletion
of TCD4, FoxP3 from untreated control.

This dose dependent depletion of TCD4, FoxP3 is consistent with that seen for G418, and
was not noted with increasing doses Zeocin or Rapa. An increase of TCD4, FoxP3 was noted with
increasing doses of Zeocin, yet this was insignificant, similar to that seen for other cytotoxic
drugs in Figure 19B-II. A representative flow plot of CD4 and FoxP3 expression from the same
donor can be seen in Figure 23B. Here, the trends can be visualized.

It was considered that polyclonal stimulation may play some part in the G418 depletion
of TCD4,

FoxP3.

To test this, PBMC were rested in CM for 9 days after thawing +/- G418 and

tested for the presence of TCD4, FoxP3. Significant depletion of TCD4, FoxP3 by G418 persisted under
resting conditions (Figure 23C – left panel). This was replication dependent as
CD4+,FoxP3+,Ki-67+ cells showed significant G418 mediated depletion while CD4+,FoxP3+,Ki67neg cells were not significantly depleted by the same post-Hoc measure (Figure 23C – right
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Figure 23
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Figure 23 Ribosomal Inhibition by aminoglycosides selectively depletes replicating TCD4,
FoxP3.

Prior experiments demonstrated that G418 depleted TCD4, FoxP3 in stimulated bulk PBMC. It

was then tested whether this action of G418 included other drugs within the aminoglycoside
class. G418 and hygromycin are aminoglycoside antibiotics known to inhibit translational
elongation. Zeocin is an antibiotic that does not target the ribosome. Thawed PBMC were
stimulated with anti- CD3/ CD28 and IL-2 in the presence of increasing concentrations of G418,
hygromycin, zeocin, or rapamycin for 7 days and the selection for TCD4, FoxP3 is shown in A. Flow
plots of FoxP3 and CD4 expression in B show the representative trends for one donor following
the use of each drug. The loss of TCD4, FoxP3 was tested in un-stimulated, thawed PBMC over the
course of 9 days with or without G418 as shown in C - top panel while C - bottom panel
shows the effects of G418 on proliferating and non-proliferating TCD4, FoxP3 as indicated by Ki-67.
Representative flow plots for one donor demonstrate the effect of G418 on CD4 and FoxP3
expression in D - top panel while FoxP3 and Ki-67 expression are shown in D - bottom panel.
Gentamicin is an FDA approved aminoglycoside antibiotic and was subsequently tested in
comparison to G418 for depletion of TCD4,

FoxP3

over a 7 day period. All experiments were

performed with 6 normal donors and repeated independently twice. Kruskall-Wallis was used
for A, Mann-Whitney used for C – top panel, and Two-Way ANOVA with Sidak’s post-hoc or
post-hoc Mann-Whitney t-tests in C - bottom panel, One-Way ANOVA with Sidak’s post-hoc in
E; * = p < 0.05, ** = p < 0.01, *** = p < 0.001 # = p< 0.05 for post-hoc t-test.
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panel). Representative flow diagrams of resting PBMC in Figure 23D – upper panel show the
loss in expression of FoxP3 for CD4+ T cells after treatment with G418. An alternative view of
Ki-67 and FoxP3 expression in Figure 23D – lower panel demonstrates that FoxP3neg T cells
continue to proliferate in the presence of G418, further supporting the selective targeting of
G418 to TCD4,

FoxP3

at this concentration. Thus, proliferating TCD4,

FoxP3

are depleted following

treatment with aminoglycoside G418.

As G418 and hygromycin are considered toxic to live animals, gentamicin, an
aminoglycoside well known for its use in humans and animal models,[147] was tested for
selective TCD4, FoxP3 depletion. Figure 23E depicts this depletion of TCD4, FoxP3 in resting PBMC
after 7 days and demonstrates the consistent action of aminoglycosides in depleting TCD4, FoxP3.
It was next tested whether depletion of TCD4,

FoxP3

corresponded with a loss of Treg marker

expression or selective Treg toxicity.

Sorted Treg differentiate the effects of MTX, 5-FU, and G418 on selection in bulk PBMC.
Magnetic sorting for CD4 and CD25 expressing PBMC yielded a CD4+ CD25+
population that is widely considered to contain Treg, and a CD25neg population of effector T cells
(Teff).[113] These populations were treated with the same concentrations of MTX, 5-FU, G418, or
no treatment, as above, for the first 7 days of co-culture with AaPC. After this period of time,
co-culture continued without drug by stimulating with AaPC every 7 days until Day 21. Cells
were assayed at this time for expression of CD25, CTLA-4, LAP, and IL-2, as before. The
experimental outline can be seen in Figure 24A. A [3H] thymidine incorporation assay was also
performed to determine the effect of each drug on the functionality of propagated Treg.
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Figure 24
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Figure 24 The effects of MTX, 5-FU, and G418 in sorted Treg. PBMC were depleted of
CD4neg cells and the remaining CD4+ cells were magnetically separated by CD25 with the
CD25+ cells cultured as Treg and CD25neg cells cultured as Teff. Each group of T cells was cocultured as before with AaPC at a 1:1 ratio and stimulated weekly for 3 weeks. The Treg and Teff
were treated with MTX, 5-FU, or G418 as before for 7 days before stimulating without drug for
the remaining 2 weeks of the experiment, which is diagrammatically shown in A. On Day 21,
markers and activity of Treg were assessed to determine the contribution of each drug to
selection or depletion of Treg, and the live TCD4, FoxP3 on Day 21 are shown in B. Each group of T
cells was then stimulated to assess expression of known Treg markers. After stimulating with
soluble anti-CD3/ CD28 and IL-2 for 48 hours T cells were assessed for co-expression of
FoxP3 with CD25 in C – I, FoxP3 with CTLA-4 in C- II, and FoxP3 with LAP in C – IV. Six hours
of stimulation with PMA/ ionomycin was used to assess loss of IL-2 secretion in FoxP3
expressing T cells, C – III. A 72 hour suppression assay was performed by mixing treated Treg
with untreated Teff and looking at uptake of [3H] Thymidine at two separate concentrations,
shown in D. This experiment was performed with 5 normal donors and repeated twice. All
experiments were assessed with Two-Way ANOVA and significance was determined by
Sidak’s post-hoc analysis; * = p < 0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001.

126

When the surviving CD4+ cells were assayed on day 21 it was found that no drug
significantly selected for TCD4,

FoxP3

in the Teff compartment, nor did MTX and 5-FU improve

selection for TCD4, FoxP3 in the Treg compartment (Figure 24B). The most consistent finding was
that G418 persistently decreased surviving Treg following drug treatment. This was
demonstrated by loss of surviving TCD4, FoxP3 (Figure 24B). Treg markers such as CD25 (Figure
24C-I), CTLA-4 (Figure 24C – II), decreased IL-2 expression (Figure 24C – III), or LAP
(Figure 24C – IV), in combination with FoxP3 expression was also decreased following
stimulation on day 21. Thus, Treg are lost, likely due to toxicity of G418, rather than inhibited as
2 weeks of growth promoting co-culture conditions could not sufficiently restore Tregs following
G418 treatment.

The Treg promoting properties of MTX and 5-FU appeared to depend in part upon the
presence of Teff, as the enhanced selection of TCD4, FoxP3 was no longer noticeable after Teff were
removed from the culture system (Figure 24B). The improved selection towards Treg
phenotypes may have been accomplished by depletion of Teff which are known to contaminate
Treg sorting.[113] It is likely that the ability of Treg to survive the cytotoxic insult of MTX or 5-FU in
comparison to Teff was a primary component of the enhanced selection. Although there was a
trend towards improved selection of Treg phenotypes (Figure 24C – I, II, III) when MTX or 5-FU
was used, there was no significant difference for expression of CD25, CTLA-4, or loss of IL-2.
However, the Treg- specific marker LAP was significantly increased by early treatment with MTX
or 5-FU (Figure 24C – IV). As LAP was the only increased marker of those assayed, it is likely
that LAP and the associated expression of TGF-β
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[143]

was the probable cause for improved

suppression of MTX and 5-FU treated Treg above untreated Treg (Figure 24D). Thus, MTX and
5-FU appear to have two components in enhancing selection of Treg: 1) Teff are selectively
depleted by MTX and 5-FU, and 2) MTX and 5-FU increase the expression of LAP weeks after
treatment.

Stimulation of TCD4, FoxP3 enhances AMPK activation and leads to inhibition of eEF2 – a
factor essential to translational elongation.

AMPK is hypothesized to play a role in selection of TCD4, FoxP3, as noted above (Figure
22). Furthermore, we hypothesized that enhanced activation of AMPK leads to inhibition of
eEF2 in TCD4, FoxP3.[135] Preferential inhibition of translational elongation could explain selection
for TCD4, FoxP3 in the presence of many cytotoxic drugs and depletion of TCD4, FoxP3 in the presence
of inhibitors of translational elongation. We tested this hypothesis by assessing phosphorylation
of AMPK 24 hours after activation of PBMC using flow cytometry (Figure 25A & B) and
imaging cytometry (Figure 25C). The phosphorylation of AMPK on T172 indicates
activation,[136] and was enhanced in stimulated over unstimulated TCD4,

FoxP3.

This enhanced

activation of AMPK was increased in CD4+, FoxP3neg T cells (Figure 25A – upper panel) as
well, but the significant increase (p = 0.03 by t-test) did not persist following post-hoc analysis.
Likewise, flow plots of activated AMPK with FoxP3 show this enhancement of AMPK activation
is much more noticeable in the FoxP3-expressing subset (Figure 25B – upper panel).[148] A
marker of translational initiation –S6 – is susceptible to mTOR regulation, and is
phosphorylated when active.[139] Phosphorylation of S6 (p-S6) was significantly enhanced in
TCD4,

FoxP3

following stimulation (Figure 25A – lower panel), which was previously shown by
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Cabone et al.[149] While p-S6 increased in the FoxP3neg T cells (p = 0.01 by t-test), this increase
was not significant following post-hoc analysis. The enhancement of p-S6 is observable in the
representative flow plot for Figure 25B – lower panel. The activation of metabolic regulators
AMPK and S6 was enhanced in both FoxP3+ and FoxP3neg CD4+ T cells following activation,
but the increase was only significant in TCD4, FoxP3 in a Two-Way ANOVA with post-hoc Sidak’s
test. The increased activation of AMPK and S6 following activation of TCD4, FoxP3 can be seen
with image cytometry profiles shown in Figure 25D before – top panel – and after stimulation
with anti-CD3/ CD28 and IL-2– bottom panel. The same compensation and visualization were
applied to each panel making the top and bottom panels comparable.
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Figure 25
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Figure 25 Stimulation of TCD4, FoxP3 enhances AMPK activation and leads to inhibition of
translational elongation factor eEF2. AMPK was hypothesized to mediate selection of TCD4,
FoxP3

under cytotoxic conditions. PBMC were stimulated with or without anti- CD3/ CD28 and IL-

2 for 24 hours and flow cytometry was used to assess phosphorylation status of AMPK in TCD4,
FoxP3.

Differentiation of TCD4, FoxP3 from CD4+ CD25neg T cells was accomplished by gating in the

stimulated and unstimulated experiments. A – top panel, depicts the mean fluorescence
intensity (MFI) of AMPK activated by phosphorylation at T172 after stimulation while A – lower
panel depicts the MFI of activated S6 by phosphorylation at sites S235/ S236. A flow plot
depicting the changes in phosphorylation for TCD4, FoxP3 and CD4+ CD25neg T cells is seen in B –
upper panel for AMPK and B – lower panel for S6 with respect to FoxP3 expression in gated
CD4+ cells. An image cytometry gallery in C shows fluorescent and morphologic changes in
TCD4, FoxP3 following stimulation. Activation of AMPK was found to be more robust in TCD4, FoxP3
and it was further hypothesized that this activation led to preferential inhibition of translation
and cell cycle progression by inactivation of translational elongation through eEF2. Inhibitory
phosphorylation of eEF2 at T56 was assessed following 24 hours of stimulation, as before. An
image cytometer was used to analyze p-eEF2 T56 MFI and depicts an increase unique to
activate TCD4,

FoxP3

in D. This difference from CD4+ FoxP3neg T cells is shown with an image

cytometry gallery in E. All experiments were repeated independently at least twice with 6
biological replicates. Two-Way ANOVA with Sidak’s post-hoc used in all analyses; * = p < 0.05,
** = p < 0.01.
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Enhanced activation of AMPK in TCD4,

FoxP3

suggests translational elongation may be

inhibited by phosphorylation of eEF2 and could account for the increased survival of TCD4, FoxP3
in the presence of cytotoxic drugs and susceptibility to inhibitors of translational elongation, like
aminoglycosides. We performed the same experiment as in Figure 25 A-C to assess the
inactivation of eEF2 by phosphorylation at T56.[135] Image cytometry was used to quantify and
visualize all events. Figure 25D demonstrates a significant increase in phosphorylation of eEF2
in the same subset of T cells - TCD4, FoxP3 - following stimulation. Also, inhibitory phosphorylation
of eEF2 was significantly increased above stimulated FoxP3neg T cells, which was not noted
with AMPK or S6 phosphorylation. The increased phosphorylation of eEF2 only in stimulated
TCD4, FoxP3 suggests that TCD4, FoxP3 would have decreased replicative capacity upon stimulation,
as shown by Cao et al.[141] As decreased levels of active eEF2 inhibit progression through the
cell cycle,

[150]

it also suggests that increased phosphorylation of eEF2 may account for the

survival of TCD4,

FoxP3

in cytotoxic environments, which was noted in Figure 19. Similarly,

decreased translational capacity would make TCD4, FoxP3 increasingly susceptible to inhibitors of
translational elongation, as was shown with aminoglycosides in Figure 23. Therefore, the
activity of eEF2 may be the primary factor influencing both selection and depletion of Treg in
these studies.

DISCUSSION:

In this study, we further the understanding of TCD4, FoxP3 selection by MTX and 5-FU in
humans, and determine that these cells constitute Treg by functional expression parameters of
CD25, CTLA-4, LAP, and loss of IL-2. Prior studies by Tohyama et al.,
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[115]

in human cells

described this phenomenon but had not determined how these drugs enhanced selection of
TCD4,

FoxP3.

Using recently described transgenes resistant to the actions of MTX and 5-FU on

DHFR and TYMS, we developed an understanding that each drug operates independently of
folate and thymidine synthesis to select for Treg. While the action of MTX on DHFR and the
action or 5-FU on TYMS are the commonly understood mechanisms for anti-cancer efficacy,
both drugs have alternative targets that promote tumor killing.[85, 86] Our study demonstrates that
these alternative actions of each drug promote a Treg phenotype in surviving cells. Prior findings
show MTX enhances AMPK activation through the inhibition of AICARtf and accumulation of
AICAR which activates AMPK.[137] This action of MTX was hypothesized to promote Tregs,

[123]

but we found that specific inhibition of AICAR synthesis was neither toxic to T cells nor
selective for TCD4, FoxP3. This essentially ruled out AICARtf inhibition as the primary means of Treg
selection. However, FoxP3 expression in TCD4,

FoxP3

was enhanced by the specific action of

AICARtf inhibition, suggesting some action of AMPK may improve Treg phenotype. Isolated Treg
studies resolved this issue by determining that the action of MTX was twofold. 1) Selection of
Treg is dependent on the depletion of Teff, as removal of Teff prevents the selective increase of
Treg following MTX treatment. 2) The action of MTX does enhance Treg functional activity in
some regard as LAP expression and suppression of Teff proliferation were increased above
untreated Treg. The activation of AMPK in the absence of folate depletion by MTX was achieved
in the transgenic T cell experiments and increased the percent of T cells with a functional Treg
phenotype. Thus, MTX depletes Teff and promotes an immunosuppressive Treg phenotype.
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Use of MTX consistently depleted CD8+ T cells in transgenic experiments to leave
primarily CD4+ T cells even when MTX toxicity was rescued by resistant DHFRFS and/ or
TYMSSS. This suggests that CD8+ T cells may be more susceptible to AMPK signaling. A
higher replication rate could exceed the capacity of the transgene to rescue transgenic cells.
This is more likely the case as both 5-FU and G418 also resulted in CD4+ T cell predominance
following transgenic rescue, although neither drug is known to signal through AMPK. A
decreased replicative rate of Treg is also supported by the finding of increased AMPK activation
and increased eEF2 inactivation. Translational elongation factor eEF2 is the primary means of
ribosomal elongation,

[135]

and inhibition would significantly impede translation and progress

towards cell division.[150] Therefore, activated Treg grow slower and take longer to succumb to
any genotoxic insult, even one which will eventually kill all cells. This is consistent with findings
in this study and others, where pan-cytotoxic γ-irradiation or chemotherapy selected for Treg.[114]
The selective inhibition of eEF2 in Treg has clear biological implications in slowing suppressive
mechanisms during early poly-clonal activation to permit the development of a sufficient
immune response.

While the action of MTX in selecting for Treg appears to be well delineated by our
experiments, the action of 5-FU in Treg selection is not as clear.

It was determined that

depletion of Teff by 5-FU is required to improve selection for Treg in culture, as with MTX. It was
also found that 5-FU acted independently of TYMS to select Treg by increasing LAP expression
and suppression of Teff proliferation. Both actions of 5-FU were similar to MTX but independent
of thymidine synthesis. In the pathway diagram in Figure 22, we hypothesize that 5-FU
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inhibition of ribosomal processing[85, 99] independently led to inhibition of eEF2, which is known
to occur during ribosomal stress.[151] This hypothesis has not yet been tested, but would support
our findings that MTX and 5-FU in combination enhance the selection of Treg independent of
thymidine synthesis and that the addition of 5-FU improves Treg selection above MTX alone.

A novel finding of our study was that aminoglycosides deplete Treg at high doses. This
finding was supported by rescue of Treg from G418 mediated depletion when Neomycin
resistance gene, which prevents G418 toxicity,[45] was present. Furthermore, multiple
aminoglycosides were able to decrease the percent of TCD4, FoxP3, and studies in isolated Treg
demonstrated that this treatment was specifically toxic to Treg. The mechanisms through which
aminoglycosides mediate toxicity are diverse,[147] and were not addressed in these studies. We
hypothesize that inhibition of mammalian translational elongation eEF2 was the factor
determining aminoglycoside susceptibility. G418 and gentamicin have been shown to inhibit the
human and mitochondrial ribosomes at the concentrations used,

[152]

and could logically

combine with inhibition of translational elongation in Treg to mediate cell death.

While

aminoglycosides have been in use for several decades the capacity of this drug to deplete Treg
has not been described. The most likely explanation for this is that the drug is used at much
lower doses in vivo than those used to deplete Treg in vitro, and is often discontinued for toxicity
to multiple tissues.[147] Also, due to toxicity, aminoglycosides are often second-line antibiotic
therapeutics limited to critically-ill patients with systemic infection[153] where gross immune
dysregulation is confounded by the mechanisms known to perpetuate sepsis.[154] We are in the
process of testing whether aminoglycosides effectively deplete Treg in vivo, and if this is the

135

case, then pretreatment with aminoglycosides may become an effective means of enhancing
anti-tumor immunity. This finding needs to be further developed in vivo before any conclusions
can be made.

In conclusion , this study develops a mechanistic understanding of how multiple
chemotherapeutics select or deplete Treg through AMPK activation and decreased eEF2
activity. Understanding how Treg are selected and depleted can inform drug design and drug
combination choices in the clinic. Here, we develop a better understanding of MTX, a first-line
anti-inflammatory drug, and demonstrate that selection of Treg may be improved by combination
with low-dose 5-FU or occasional addition of leucovorin to rescue slowly replicating Tregs from
inhibition of folate and thymidine synthesis. These findings open up new understandings in the
methods to target and treat disease as well as possible mechanisms of dysregulation in
autoimmune disease.
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CHAPTER 5 Discussion and Future Directions
SYNOPSIS

These studies were developed with the intention of improving T cell therapeutics. Each
aim is intended to expand the repertoire of in vitro ASIS methods and enhance the selection of
desired T cells. While the objective of each study was achieved, the studies are limited to in
vitro work. No in vivo data has been included in these studies to suggest that any of the
phenotypic findings extend beyond in vitro observations. This is a clear caveat of this system.
However, working with human cells has benefits and limitations, and an example will help in
understanding this statement; a limitation might be that the depletion of Treg by aminoglycosides
is not reproducible in a murine model, yet aminoglycosides could still target Treg in human cells.
In fact, human Treg are well known to differ from murine Treg by phenotypic markers.[113] As
aminoglycosides are a full class of FDA approved drugs with well-known pharmacokinetics and
side effects,[153] the depletion of Treg could more easily be tested in humans in small scale
clinical trials. This brings into question the necessity of an animal model for studies originally
designed for human cells, as animal models have different biological backgrounds.

There is another limitation of animal models in that they do not recapitulate the natural
cellular environment. Consider CARL+ K562 as one example; CARL+ K562 could be compared
with standard AaPC (clone.4) to assess differences in outcomes for patients receiving CAR+ T
cell therapy. An animal model designed to assess the in vivo functionality of CAR grown on
differing AaPC would utilize immunocompromised mice with xenograft tumor and xenograft T
cells. With a few exceptions, these models do not recapitulate many aspects of the human
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body or an intact immune system.[26] In the standard NSG mouse model there are no
endogenous B cells or T cells, and a dysregulation in macrophages, this would clearly alter the
environment experienced by CAR+ T cells and the immune response induced by the reaction of
these cells towards the tumor.[155] It is a reasonable argument that an animal model assessing
the differences between AaPC would miss potential differences between the two AaPC that
could lead to gross differences in tumor eradication and patient survival. Thus, it might be more
prudent to test AaPC differences directly in humans. In a clinical trial, a product with equivalent
CAR expression on T cells could be compared for differences induced by growth on differing T
cells whether propagated on CARL+ K562 or clone.4 K562. A clinical trial, while more
expensive and complicated, would yield much more relevant data than a mouse model.
Therefore, certain changes to methodology, such as novel in vitro ASIS methods might be
better assessed in humans rather than mice.

Notwithstanding, a murine model would still be quite useful in assessing whether certain
experimental findings can be repeated in an in vivo model. As an example, DHFRFS selected
with MTX and grown on clone.4 AaPC yielded an almost uniform increase in the CD4+ T cell
population in multiple experiments, while DHFRFS selected by MTX and grown on CARL+ K562
through CAR did not change the CD4+ T cell predominance. This finding was difficult to explain,
even though it was consistent with the published findings of others.[82] Based on our
subsequent studies with MTX, it is likely that MTX was inducing activation of AMPK in our
DHFRFS+ CAR+ T cells as well as the DHFRFS+ CAR+ T cells published by Jonnalagadda et
al.[82] The long-term effects of AMPK activation is uncertain for CAR+ T cells and could be
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beneficial[156] or detrimental[157] based on available data. An animal model would be ideal for
discriminating the true outcome of this alteration in signaling.

Overall, the data presented here is limited to in vitro studies and some aspects of the
work remain to be resolved with further in vitro and in vivo studies. However, we believe that
the aims and objectives were sufficiently achieved within our system to discuss the implications
of this work on future preclinical and clinical studies. We believe that the following primary
findings are not unique to our system and have biological and clinical implications:

1) Genetically-modified T cells can be selected and propagated independent of
antigen-specificity based on the use of a CAR containing a conserved domain that is
recognized and ligated by CARL+ AaPC.
2) Genetically-modified T cells can be selected and propagated independent of
antigen-specificity utilizing AThyR transgenes DHFRFS and TYMSSS individually or
together.
3) AThyR transgenes DHFRFS and TYMSSS confer special properties to T cells in the
presence of MTX:
a. Cis-transgene co-expressed with DHFRFS can be titrated or up-regulated by
applying varying concentrations of MTX
b. Co-expression of TYMSSS with DHFRFS blunts the findings noted in a.
c. Co-expression of TYMSSS with DHFRFS confers improved resistance to MTX
d. Application of MTX in DHFRFS expressing T cells appears to perturb
signaling pathways.

139

i. This is likely achieved through the AMPK pathway, but this remains
to be proven
4) Consistent selection of AThyR transgene TYMSSS depends upon the depletion of 5FU resistant T cells.
5) High-dose aminoglycosides selectively deplete Treg in culture
i. This is likely mediated by eEF2 inhibition, but remains to be proven
6) MTX and 5-FU enhance selection of Treg in culture
a. Through selective depletion of Teff
b. Through enhanced expression of LAP, associated with TGF-β
These findings were briefly discussed above. Here the biological context will be discussed with
clinical implications discussed in the following section.

The objective to establish novel, transgenic, in vitro ASIS methods for T cell
therapeutics has been achieved. We believe these technical improvements will make T cell
therapy a safer and more reliable treatment option. Transgenic modifications to T cell products
have been attempting to improve safety and reliability for decades.[43, 158] Unfortunately, these
advances have suffered from technical issues and the immunogenicity of the transgenes
chosen.[41,

159]

As an example: The earliest reports of gene modification in human cells used

drug resistance to select for transformed cells,[160] and drug resistance was the first reported
gene modification in human T cells.[161] Drug resistance in T cells,
MTX in T cells,

[46, 82]

[161]

including resistance to

has been under-utilized due to technical limitations regarding the

transgenes chosen. That being transgenes originating from bacteria and viruses are
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immunogenic[41, 159] while the non-immunogenic transgene resistant to MTX is not useful in the
context of most cancers where higher doses of MTX and MTX analogs with higher antithymidylate activity make transgenic resistance to MTX obsolete in vivo.[86] The technological
advance reported here include the use of transgenes to confer a broader spectrum of
chemotherapeutic drug resistance to common anti-thymidylate drugs, and the capacity to utilize
these transgenes to modify expression of cis expressed transgenes for in vivo use. Likewise, it
is possible that these drug resistance transgenes can alter signaling pathways responsible for
T cell selection and survival when combined with MTX. Thus, the findings here expand the
number of transgenic options for in vitro ASIS while increasing the in vivo utility of choosing
these transgenes. For this reason we suspect that these transgenes will be integrated into
strategies to select and deplete T cell therapeutics in vitro and in vivo achieving the overall goal
of improving safety and efficacy in T cell therapeutics.

As mentioned, MTX-dependent alterations in transgene expression and intracellular
signaling could be useful to manipulate T cell phenotype in vitro or in vivo towards a desired
outcome. In transgenic T cell studies, phenotypic alterations tend to modulate survival and
growth or apoptosis and cell death. An example of selection for survival is the transgenic
modification of T cells to over-express Bcl-2, an inhibitor of apoptosis, to prevent T cell
death.[162] A study by a different group utilized a constitutively active form of AKT to enhance T
cell activity and survival.[163] These modifications, however, were independent of drug induction.
Drug-dependent modifications to T cell phenotype are best exemplified by suicide genes.
Suicide genes such as herpes simplex virus – thymidine kinase (HSV-TK)
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[158]

and inducible

caspase 9 (iC9)

[36]

which induce T cell death when drug is added. However, prior to the

addition of drug, these genes are not believed to substantially alter the phenotype of the T
cell.[35]

The drug-inducible modification of T cell phenotypes has broadened as several groups
begin to explore the chimerization of cytokine signaling. The signaling of cytokine IL-4, which
signals towards a Th2 phenotype in T cells and away from a cytotoxic Th1 phenotype[5] was
chimerically modified to provide a proliferative Th1 signal to T cells similar to that of IL-2 or IL15. Although this signal utilized an endogenously produced IL-4, the protein could be used ex
vivo to expand T cells by selectively altering biochemical signaling pathways.[42] This concept
was later used by another group to transduce the extracellular presence of IL-4 into the
intracellular signal of IL-7 in genetically-modified T cells. Ultimately the modified T cells were
used in vivo to enhance clearance of IL-4 secreting tumors in a xenogeneic mouse model.[164]
The use of endogenous proteins, such as IL-4, limits the capacity to selectively activate
biochemical pathways in transgene expressing T cells. That is because systemic administration
of IL-4 to a patient, while not as toxic as IL-2, and more selective towards transgenic T cells
than IL-7 or IL-15, still has off-target effects on other immune cells and the entire body.[165, 166] In
another study, a non-endogenous protein was used to activate cytokine signaling. A common
protein was chemically conjugated with multiple small molecules. A scFv-specific to the small
molecule was chimerized by the addition of the modified protein and led to intracellular
signaling in murine B cells. In this way, a drug with little direct physiological effects was used to
cross-link and initiate biochemical signaling within the transgenically modified cells.[167] The use
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of chimeric proteins to alter cytokine signaling of endogenous human proteins will likely
continue. A recent abstract presentations detailed the chimerization of a TGF-β receptor with
TLR4 signaling endodomains to remove the physiologic suppression of TGF-β on T cells.[168]
Thus, the use of drug-susceptible transgenes to augment T cell phenotypes rather than ablate
transgenic T cells is in a nascent stage. Above are the few reported transgenes targeting
biochemical pathways. Here we suggest a novel transgene to target a biochemical signaling
pathways. Also, we propose a different biochemical pathway than the cytokine signaling
pathways typically targeted.

Here we propose a novel method to selectively activate AMPK in the presence of MTX.
This developed from the observation that MTX, in combination with DHFRFS, resulted in
different T cell phenotypes depending on the context (reference Ch. 3 Figure 12 & 17, Ch. 4
Figure 19 & 21). In Chapter 4, it was outlined how AMPK contributed partly to Treg outgrowth,
and that DHFRFS when combined with MTX appears to stimulate the AMPK pathway towards
enhanced Treg outgrowth. This was noted in strong stimulatory conditions where polyclonal CD3
crosslinking was combined with strong costimulatory signaling. In these experiments, MTX
treatment of DHFRFS-expressing cells resulted in CD4+ T cells predominance compared to untransformed T cells (Ch. 3 Figure 12). This should be contrasted with experiments where CAR+
T cells received stimulation solely through the stimulatory and costimulatory domains of CAR
(Ch. 3 Figure 17). In the DHFRFS+, CAR+ T cell experiment, there was no difference from unmanipulated T cells in CD4+ predominance. This isolated experiment, while consistent on
repetition, appears to conflict with DHFRFS+ T cell experiments not using CAR.
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A resolution to this conflict may be understood by making note of initial experiments
with DHFRFS not presented here. Initial constructs of DHFRFS were designed to co-express with
CD19-specific CAR as DHFRFS-2A-CAR on T cells. Attempts to grow T cells expressing
DHFRFS-2A-CAR on the strongly stimulatory AaPC clone.4 expressing CD19, CD86, and
CD137L, resulted in multiple failed experiments where CAR+ T cells did not selectively
propagate in the presence of MTX (data not shown). Consequently, the development of an
AaPC with no costimulation, CARL+ K562, permitted the propagation of DHFRFS-2A-CAR and
the construct was easily developed, tested, and reported.[169] Therefore, CD3 and costimulatory
signaling clearly play a role in toxic drug mediated depletion of CD8+ T cells.

These experiments reported above were not designed for direct comparison and do not
explicitly comment on the capacity of AMPK to select for one phenotype over another in the
context of costimulation. With that noted, there have been a number of studies on AMPK
signaling in the context of T cell activation that will assist in understanding this phenomenon:
AMPK is considered a negative regulator of T cell activity.[170] T cell activation leads to a
metabolic switch to glycolysis that is required to sustain the rapid proliferation and biosynthetic
pathways of an inflammatory T cell.[171] AMPK mediates an antagonistic signal against
glycolysis and towards lipolysis, inhibiting biosynthetic pathways, and inhibiting proliferation, at
least in part through inhibition of mTOR.[136] T cells deficient in AMPK lead to excessive
inflammation and poorer outcomes in an animal model of disease such as experimental
autoimmune encephalomyelitis (EAE).[157] Activation of AMPK also decreases lymphocyte
involvement and disease severity in an experimental asthma model.[172] Loss of AMPK in T
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cells results in excessive activation of CD8+ T cells towards an inflammatory phenotype of
increased IFN-γ secretion.[148] The un-opposed switch towards glycolysis in CD8+ T cells
prevents CD8+ T cell memory development, and AMPK deficient T cells fail to survive after the
initial response to antigen.[156] The excessive secretion of cytokines seen in AMPK deficient
CD8+ T cells was not noted in AMPK deficient CD4+ T cells.[148] On the opposite end of the
spectrum, activation of AMPK during the experimental asthma model did decrease CD4+ T cell
numbers and promoted Treg outgrowth.[172]

The above studies, all performed in mice, confer with our findings in human cells; AMPK
activation in CD4+ predominant T cells activated by TCR and costimulation leads to increases
in Tregs. As mentioned the AMPK activation leads to mTOR inhibition,[136] and T cell specific
mTOR knockouts in mice resulted in increases in the Treg population

[173]

similar to that seen

with enhanced AMPK activation via metformin.[172] This points to the hypothesis in CD8+ T cells
that rescue from drug depletion by CAR-mediated expansion will permit AMPK inducible T cell
memory formation in DHFRFS, CAR+ T cells. An important component of this hypothesis is that
administration of MTX to DHFRFS+ T cells will lead to AMPK activation in CD8+ T cells. It has
been shown that inhibition of mTOR in CD8+ T cells following activation results in improved T
cell memory upon repeat presentation of antigen.[174] Thus, the use of CAR with DHFRFS could
potentially be used to selectively activate CD8+ T cell memory in transgenic T cells with the
addition of MTX. This would constitute an attractive and novel method of selectively activating
biochemical pathways to promote a desired T cell phenotype.
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In conclusion, our studies start by developing simple in vitro ASIS methods for
transgenic T cells, but lead to new strategies for understanding and manipulating the
expression of T cell phenotypes. There was no expectation that developing tools for T cell
selection and propagation would lead to a better understanding of T cell biology and novel
transgenic techniques. However, the development of new tools often precedes discovery. It
was after the development of AThyRs that we serendipitously found a method to selectively
grow Treg, and based on this finding we subsequently developed a novel method for the
depletion of Treg. The above work advocates for critical analysis of well controlled science. Had
a simple screening of CD4+ and CD8+ T cell subset predominance been neglected, a whole
avenue of Treg biology would have been missed. While this work remains incompletely
understood, proceeding with clinical and preclinical work is merited based on the findings.

CLINICAL IMPLICATIONS

Few cell therapies and no cell-based gene therapies are currently approved by the
FDA.[20] This fact does not preclude the use of some transgenic techniques reported here to be
used in Phase I – III clinical trials. CARL+ AaPC could easily be integrated into open and
ongoing clinical trials involving CAR+ T cells. However, few groups in the United States outside
of MD Anderson utilize CAR-mediated ex vivo expansion. The use of CARL may be quite
limited as it depends on the development of a novel CAR without a validated AaPC. Our group
has published three different CARs, one of which is CD19-specific CAR currently in clinical
trials with a validated clone.4 AaPC.[175] Another targeting fungal antigens has all of the
preclinical data performed using the same clone.4 AaPC as CD19-specific CAR but loaded with
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an activating antibody.[176] The third was grown on CARL+ K562,[95] but has no plans for clinical
development. Consequently, there is uncertainty with respect to further development of CARL+
AaPC, and for that reason the development and validation of a clinical-grade AaPC expressing
CARL has not yet begun. It is unlikely CARL will have any clinical impact without the
development of a clinical-grade AaPC.
In regard to the AThyR transgenes DHFRFS and TYMSSS, a combination therapy of
AThyR+ T cells with AThy therapies is, a priori, a straight-forward means to improve anti-tumor
immunity. However, our in vitro studies demonstrated that CD8+ T cells, the primary effectors of
tumor immunity,[177] are selectively inhibited from outgrowth during polyclonal stimulation. In
vivo studies would be necessary to compare this approach to re-infusion of activated T cells
following chemotherapy. Re-infusion of activated T cells following chemotherapy would be
much easier to perform than the extensive manipulation necessary to generate AThyR+ T cells.
Expressing AThyRs may be advantageous as discussed above for activating biochemical
pathways of interest or ensuring the inclusion of a suicide gene in CAR+ T cells. CAR-mediated
expansion techniques would also maintain the cytotoxic CD8+ T cell population. Consequently,
AThyRs seem to be more reasonable for use in CAR+ T cells, but the proposed uses of
AThyR+ CAR+ T cells need to be validated in vivo.

The findings of selective increase or decrease in the Treg population using FDA
approved drugs have the most immediate potential for clinical impact. Aminoglycosides, such
as gentamicin, could be used in clinical trials targeting easily localized chronic infections and
cancers. While we suspect that long-term systemic administration of aminoglycosides will
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selectively deplete Treg in preference to other T cells, we also believe that the properties that
lead to selective depletion of Treg are found in other tissues, such as the kidneys and nervous
system.[153] Based on this understanding, we seek to target diseases of a local nature, and we
propose the following clinical trials: 1) intra-lesional injection of gentamicin or penicillin (a nonaminoglycoside antibiotic) into treatment resistant verrucae (a human papilloma virus
infection)[178] with punch and excisional biopsies for assessment of inflammatory response and
Treg persistence. 2) Ultrasound guided intratumoral injection of gentamicin or penicillin in newly
diagnosed breast cancers with post-resection pathological assessment of tumor mass
reduction, inflammatory response in tumor and lymph nodes, and Treg persistence. If the above
studies are consistent with Treg depletion and reduction or loss of tumor, then the following is
proposed: 3) A randomized control trial treating metastatic melanoma and squamous cell
carcinoma with intra-tumoral injections of gentamicin or penicillin followed by checkpoint
blockade therapy involving either anti-CTLA-4[179] or PD-1 blockade.[180] We believe that this
series of clinical trials will inform clinicians on the utility of depleting Tregs in chronic infection and
cancer. We also believe this approach will avoid excessive risk to critical organs such as brain,
heart, or lung.

Finally, we found that MTX and 5-FU both increase Treg selection and improve LAP
expression in ex vivo expanded Treg. The methods described here provide a protocol for
improved ex vivo expansion of Treg. Further refinement of the drug duration and drug
combinations is necessary to develop a highly enriched and suppressive Treg population that is
of clinical-grade. The combination of MTX with 5-FU may enhance suppressor cell outgrowth
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when folate synthesis is rescued. It was seen in our in vitro model, and recapitulating the
finding in vivo could lead to a new drug combination for the treatment of inflammatory
disorders. A rodent model of an inflammatory disorder commonly treated by MTX such as
rheumatoid arthritis (RA)[104] could be tested in conjunction with low-dose 5-FU and folinic acid
replacement. Folinic acid, also called leucovorin, is commonly used to rescue folate synthesis
during the treatment of high dose MTX.[181] If the animal model is consistent, a clinical trial in
RA could assess the additional benefit versus toxicity of MTX plus low-dose 5-FU with folinic
acid rescue in comparison to MTX alone.

FUTURE DIRECTIONS
The potential of CARL+ K562 to expand CAR+ T cells independent of antigen served as
a simple tool to decrease the time required to thoroughly test and validate new specificities of
CAR. We also noted CARL provides a unique opportunity to understand the influence of CAR
signaling differences from typical T cell activation by TCR and co-stimulation. To further
develop CARL as a tool in dissecting the optimal configuration of CAR, improvements in the
CAR specificity towards CARL may be necessary. In studies (not shown here) defining the
specificity of CARL towards CAR, it was determined that the likely binding region of CARL on
CAR is in the CH3 domain of the IgG4 Fc stalk expressed on CAR. This is advantageous as all
immunoglobulin Fc receptors bind IgG in the CH2 domain.[182] Fc receptors on the AaPC, such
as CD32 or CD64, can ligate and activate CAR+ T cells containing the native CH2-CH3 IgG4
with intact Fc binding domain (not shown here). While ligation via the Fc receptor may seem a
simpler method to activate and expand CAR in vitro, CAR binding Fc receptors could lead
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researchers to frivolous experiments and wasted time trying to explain inconsistent cytotoxicity
of CAR+ T cells which is due to Fc binding rather than antigen specificity. The potential to bind
Fc receptors in vivo also remains an issue. This has been observed both in vitro and in vivo by
Jonnalagadda et al., where unmodified CAR Fc led to deleterious Fc binding in vitro and
removal by myeloid cells in vivo. A mutation to the Fc binding sites of CAR IgG4 domain or
removal of the CH2 domain abrogated these deleterious findings and led to improved survival in
a xenograft mouse model.

[183]

To avoid this issue, we tested CAR containing mutations to the

Fc binding regions of IgG4, as was done by Jonnalagadda et al., and observed no changes in
the activation and propagation of CAR+ T cells by CARL (not shown here). Thus, CAR with the
appropriate Fc mutations, or quite possibly only containing the CH3 domain, will be able to
expand on CARL+ AaPC free from deleterious binding. The ability to ligate any specificity of
CAR on the surface of a T cell without the risk of off-target activation opens up the potential to
refine CAR+ T cell specificity and phenotype.
CARL+ AaPC could be used to define the optimal signaling and antigen specificity
requirements of CAR+ T cells in comparison to equivalent activation by TCR and costimulation.
Currently, the field is trying to determine the optimal antigenic targets, scFv specificities, and
endodomain signaling strengths to develop a CAR+ T cell that strongly targets and kills tumor.
At the same time, the development of a proficient memory subset of T cells is sought to
respond to resurgence of tumor associated antigen.[25] A philosophical divide is developing over
what CAR design will best meet these needs;[25] a CAR with antigen specificity and
costimulatory signaling occurring in series, or multiple antigen specificities with costimulatory
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signaling occurring in parallel (See Figure 26A). The CAR protein that has already been
described uses in-series activation, where each signaling domain is attached in series to the
next signaling domain. Second-generation CAR signaling is in-series and a single scFv
mediates a combination of TCR signal via CD3ζ and a costimulatory signal. The choice of
costimulation is also contentious, but tends to be either CD28 or CD137.[24] Costimulation is not
limited to one or two costimulatory signals and some authors have included multiples of
costimulatory endodomains.[72] In parallel signaling uses several different specificity scFvs each
promoting a different stimulatory or costimulatory signal to activate T cells when all antigens
are present (See Figure 26A). This in parallel system was best demonstrated by Kloss et al.,
who used one CAR targeting CD19 with stimulatory domains to provide suboptimal activation
while a second CAR targeting PSMA was also expressed on the T cell to provide costimulation.
Sufficient signal for fully activating CAR+ T cells was possible when both CD19 and PSMA were
present on the same T cell, and activation was not possible if only one antigen was present on
a target cell.[184] This study was a proof of concept with in vivo demonstration of efficacy. The
idea was not new, and had been attempted in various permutations in the preceding 3 years
without in vivo testing.[185, 186] Developing in-parallel CAR+ T cells has proven to be a technical
challenge difficult to repeat among the various interested groups. This is likely due to the
challenge of testing various antigen-specific scFvs with various signal strength combinations.
Using viral vectors and no selective propagation, this is a feat difficult to comparatively test.
Viral transformation of T cells with multiple transgenes requires selection or multiple stages of
genetic transformation to develop cells sufficient for testing. CARL+ K562 presents a simple
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solution to this problem as activation of CARs by CARL will propagate even a small percentage
of T cells expressing the right combination of CARs to a uniform population. That is because
CARL will only activate and propagate CAR+ T cells deriving sufficient signal strength from
CAR. Therefore, CAR+ T cell propagation on CARL+ K562 is an independent test of sufficient
signal strength for CAR combinations. This approach is not currently possible using any other
system, and allows for testing of even more difficult questions challenging the field. One of
these questions is whether in-series or in-parallel CARs provide better signal strength for
activation and propagation. Another question is how CAR intrinsically differs from endogenous
signaling via TCR, costimulation, and cytokines. An experiment proposed in Figure 26B
demonstrates how un-modified T cells stimulated through TCR, CD28, and IL-2 - signals 1
through 3, could be compared to chimerized receptors providing signals 1 through 3. The
objective of these experiments would be to quantify differences between in-series and inparallel CAR+ T cell activation by the use of image cytometry. This study as designed would
also begin to answer questions of how CAR signaling differs from endogenous TCR signaling
by quantifying differences in signal strength across the multiple signaling pathways.
Furthermore, these findings will be correlated with high-resolution microscopy to elucidate how
localization of various CARs contribute to differences in signaling strength from endogenous
TCR. This would be the first reductionist approach towards understanding CAR design for
activation and propagation of T cells.

152

Figure 26
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Figure 26 Future studies targeting biochemical signaling in T cells. A schematically
represents CARs which signal in-series (I & II) or in parallel (III & IV). CAR I represents 1st
generation CAR, II represents 2nd generation CAR, III & IV represent in-parallel CARs, and V
represents a chimeric cytokine receptor. B shows the comparative testing of these constructs
to unmodified T cells during the canonical activation of T cells through TCR, CD28, and IL-2. C
presents an experimental approach to enhancing T cell memory using DHFRFS in combination
with MTX.
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A separate proposed study would try to optimize another key physiologic parameter of T
cells – establishing T cell memory. Here, we proposed that DHFRFS in combination with MTX
will activate AMPK, subsequently inhibit mTOR, and promote memory T cell formation in a drug
inducible manner. This hypothesis is untested in CAR+ T cells and must be further studied.
Figure 26C depicts the proposed future studies designed to test enhanced memory formation
in DHFRFS+, CAR+ T cells.

We believe that the proposed studies utilize the tools developed here to address
fundamental issues which remain in developing and translating T cell therapeutics. Hopefully,
using these tools will effectively answer questions of how to establish and maintain T cells
therapies for the eradication of disease in humans.
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